Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2022

# **Supporting Information**

# Metal-free photocatalytic intermolecular trifluoromethylationgem-difluoroallylation of unactivated alkenes

Wan-Qiang Yuan, Yu-Tao Liu, Yu-Qing Ni, Yong-Ze Liu and Fei Pan\*

College of Chemistry and Materials Science, Sichuan Normal University, Chengdu, 610068, People's Republic of China

\*Email: feipan@sicnu.edu.cn

# TABLE OF CONTENTS

1. General Information	.S01
2. Preparation of Substrates	.S02
3. Standard Reaction Conditions	S12
4. Characterization Data of Products	.S13
5. Large-Scale Experiment and Further Synthetic Transformation	.S45
6. Control Experiments	.S49
7. References	S51
8. NMR Spectra	.S52

# 1. General Information:

Unless otherwise noted, all reactions were performed in a 4 mL test tube at room temperature under nitrogen atmosphere. Photo-irradiation was carried out with a 30 W blue LED. Solvents were dried by passage through an activated alumina column under argon. Liquids and solutions were transferred via syringe. For chromatography, 200-300 mesh silica gel (Qingdao, China) was employed. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were measured in CDCl<sub>3</sub> and recorded on Brucker ARX 600 spectrometer.<sup>19</sup>F NMR spectra were measured in CDCl<sub>3</sub> and recorded on Varian 400 spectrometer. Chemical shifts ( $\delta$ ) were given in ppm, referenced to the residual proton resonance of CDCl<sub>3</sub> (7.26), to the carbon resonance of CDCl<sub>3</sub> (77.16). Coupling constants (J) were given in Hertz (Hz). The term m, t, d, s, dd referred to multiplet, triplet, doublet, singlet, doublet of doublet. Gas chromatography-mass spectrometry (GC-MS) was performed on an Thermo Fisher Trace ISQ 7000. Gas chromatography (GC) was performed on a Shimadzu GC 2010-pro system equipped with a split-mode capillary injection system and flame ionization detectors. High-resolution mass spectra (HRMS) were recorded on a Bruker Daltonics MicroTOF-Q II from Sichuan University. α-CF<sub>3</sub> alkenes were prepared according to literature reported procedures.<sup>6-8</sup> All reagents and solvents were commercially available and directly used without any further purification.

Reactions were monitored through thin layer chromatography [Merck 60 F254 precoated silica gel plate (0.2 mm thickness)]. Subsequent to elution, spots were visualized using UV radiation (254 nm) on Spectroline Model ZF-7 254 nm. Other visualization methods include staining with a basic solution of potassium permanganate or acidic solution of ceric ammonium molybdate, followed by heating. Visible light irradiation was performed with a 30 W Led lamp at  $\lambda_{ir} = 450 \pm 10$  nm for phtotcatalytic reactions. The Led lamps used in this research were brought from Sichuan Zhiyan Technology Co., Ltd. (Figure S1)

# 2. Preparation of Substrates:

#### List of alkenes 1 Monosubstituted alkene: Br Br 1d 1f 1b 1c 1e 1a -NBoc BzO 1j 1k 1h 1i 1g ö NC BocHN. 0 AcO B 11 1m 1n 10 1p 1q Cyclic alkene: **Disubstituted alkene:** Trisubstituted alkene: 0 Me 1t 1u 1r 1v 1w **1**s Tetrasubstituted alkene: Enamide and enol ether: 1z 1x 1v 1aa Natural product and drug derivatives: MeC MeO 1ab 1ad 1ae 1ac from Methyl eugenol from Ibuprofen from Oxaprozin from Estrone Me Me .Me Ü C ΌМе 1af 1ag 1ah 1ai from (1S)-(-)-Camphanic acid from Ciprofibrate from (+)-Nootkatone from Indomethacin

Alkenes 1a-1j, 1l-1o, 1r-1u, 1x-1aa, 1ae, 1af are commercially available compounds. Alkenes 1k, 1p, 1q, 1v, 1w, 1ab-1ad, 1ag-1ai were prepared according to the reported literatures.<sup>13</sup>

Method A:(For compounds 1k, 1p, 1v, 1ab, 1ac, 1ag, 1ah, 1ai)



According to the reported procedure,<sup>1</sup> a flame-dried round-bottomed flask was charged with acid (5.0 mmol, 1.0 equiv), alcohol (10 mmol, 2.0 equiv), 4-(dimethylamino)pyridine (61.0 mg, 0.5 mmol, 0.1 equiv), and dry DCM (5.0 mL, 1 M), The reaction mixture was then cooled to

0 °C, and dicyclohexylcarbodiimide solution (1M in CH<sub>2</sub>Cl<sub>2</sub>, 10 mL, 10 mmol, 2.0 equiv) was added dropwise. The reaction mixture was allowed to warm at 23 °C, stirred for 12 hours at this temperature, filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to afford the desired product.

### 1-(*Tert*-butyl) 2-(hex-5-en-1-yl) (*R*)-pyrrolidine-1,2-dicarboxylate (1k)

**1k** was prepared according to **General Method A** from commercially available (*tert*-butoxycarbonyl)-D-proline and hex-5-en-1-ol.

TLC Rf = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.75 (tt, *J* = 10.7, 6.8 Hz, 1H), 4.98 (d, *J* = 17.1 Hz, 1H), 4.93 (t, *J* = 8.6 Hz, 1H), 4.40 - 3.80 (m, 3H), 3.78 - 3.19 (m, 2H), 2.27 - 2.09 (m, 1H), 2.05 (dd, *J* = 13.7, 6.7 Hz, 2H), 1.91 (ddd, *J* = 20.0, 13.3, 7.0 Hz, 2H), 1.65 - 1.59 (m, 2H), 1.52 - 1.40 (m, 3H), 1.38 (s, 9H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 173.3, 153.8, 138.1, 114.9, 79.8, 64.8, 59.2, 46.3, 33.2, 30.9, 28.3, 28.1, 25.1, 23.6.

This matched literature characterization.<sup>1</sup>

## Allyl 2-phenoxyacetate (1p)



**1p** was prepared according to **General Method A** from commercially available 2-phenoxyacetic acid and prop-2-en-1-ol.

TLC Rf = 0.60 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.35 – 7.27 (m, 2H), 7.00 (t, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 7.9 Hz, 2H), 5.93 (ddt, *J* = 16.3, 10.4, 5.8 Hz, 1H), 5.34 (dd, *J* = 17.2, 1.4 Hz, 1H), 5.27 (dd, *J* = 10.4, 1.2 Hz, 1H), 4.71 (d, *J* = 5.8 Hz, 2H), 4.66 (s, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  168.7, 157.8, 131.4, 129.6, 121.8, 119.1, 114.7, 65.9, 65.4. This matched literature characterization.<sup>1</sup>

## 3-Methylbut-3-en-1-yl benzoate (1v)



1v was prepared according to **General Method A** from commercially available benzoic acid and 3-methylbut-3-en-1-ol.

TLC Rf = 0.80 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.04 (d, *J* = 7.4 Hz, 2H), 7.59 – 7.51 (m, 1H), 7.43 (t, *J* = 7.6 Hz, 2H), 4.83 (d, *J* = 10.9 Hz, 2H), 4.44 (t, *J* = 6.8 Hz, 2H), 2.49 (t, *J* = 6.8 Hz, 2H), 1.82 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  166.6, 141.7, 132.9, 130.4, 129.6, 128.4, 112.4, 63.2, 36.8, 22.6. This matched literature characterization.<sup>2</sup>

### Hex-5-en-1-yl 3-(4,5-diphenyloxazol-2-yl)propanoate (1ab)



**1ab** was prepared according to **General Method A** from commercially available oxaprozin and hex-5-en-1-ol.

TLC Rf = 0.45 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.66 – 7.61 (m, 2H), 7.60 – 7.54 (m, 2H), 7.39 – 7.29 (m, 6H), 5.76 (ddt, *J* = 16.9, 10.2, 6.7 Hz, 1H), 4.99 (ddd, *J* = 17.1, 3.4, 1.6 Hz, 1H), 4.94 (ddt, *J* = 10.2, 2.1, 1.1 Hz, 1H), 4.13 (t, *J* = 6.6 Hz, 2H), 3.19 (t, *J* = 7.5 Hz, 2H), 2.91 (t, *J* = 7.6 Hz, 2H), 2.05 (dd, *J* = 14.3, 7.2 Hz, 2H), 1.71 – 1.58 (m, 2H), 1.50 – 1.37 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 172.1, 161.8, 145.4, 138.3, 135.1, 132.5, 129.0, 128.6, 128.5, 128.4, 128.1, 127.9, 126.5, 114.9, 64.8, 33.3, 31.2, 28.0, 25.2, 23.6.

This matched literature characterization.<sup>3</sup>

### Hex-5-en-1-yl 2-(4-isobutylphenyl)propanoate (1ac)



**1ac** was prepared according to **General Method A** from commercially available ibuprofen and hex-5-en-1-ol.

TLC Rf = 0.70 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.20 (d, *J* = 8.1 Hz, 2H), 7.09 (d, *J* = 8.1 Hz, 2H), 5.73 (ddt, *J* = 16.9, 10.2, 6.7 Hz, 1H), 4.97 (ddd, *J* = 17.1, 3.4, 1.7 Hz, 1H), 4.93 (ddt, *J* = 10.2, 2.0, 1.1 Hz, 1H), 4.06 (t, *J* = 6.6 Hz, 2H), 3.68 (q, *J* = 7.2 Hz, 1H), 2.44 (d, *J* = 7.2 Hz, 2H), 2.01 (dd, *J* = 14.3, 7.3 Hz, 2H), 1.84 (dp, *J* = 13.6, 6.8 Hz, 1H), 1.70 – 1.52 (m, 2H), 1.48 (d, *J* = 7.2 Hz, 3H), 1.35 (dq, *J* = 15.1, 7.6 Hz, 2H), 0.89 (d, *J* = 6.6 Hz, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 174.8, 140.5, 138.4, 137.9, 129.3, 127.1, 114.7, 64.5, 45.2, 45.0, 33.2, 30.2, 28.0, 25.0, 22.4, 18.5.

This matched literature characterization.<sup>4</sup>

#### Hex-5-en-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (1ag)



**1ag** was prepared according to **General Method A** from commercially available indomethacin and hex-5-en-1-ol.

TLC Rf = 0.40 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.66 (d, *J* = 8.5 Hz, 2H), 7.47 (d, *J* = 8.5 Hz, 2H), 6.96 (d, *J* = 2.5 Hz, 1H), 6.86 (d, *J* = 9.0 Hz, 1H), 6.67 (dd, *J* = 9.0, 2.5 Hz, 1H), 5.74 (ddt, *J* = 16.9, 10.2, 6.7 Hz, 1H), 5.08 – 4.89 (m, 2H), 4.10 (t, *J* = 6.7 Hz, 2H), 3.83 (s, 3H), 3.66 (s, 2H), 2.39 (s, 3H), 2.03 (dd, *J* = 14.3, 7.2 Hz, 2H), 1.63 (dt, *J* = 14.9, 6.7 Hz, 2H), 1.46 – 1.33 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  170.9, 168.3, 156.0, 139.3, 138.2, 135.9, 133.9, 131.2, 130.8, 130.7, 129.1, 115.0, 114.9, 112.7, 111.7, 101.3, 65.0, 55.7, 33.2, 30.4, 28.0, 25.2, 13.4. This matched literature characterization.<sup>3</sup>

Hex-5-en-1-yl (1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (1ah)



**1ah** was prepared according to **General Method A** from commercially available (*1S*)-(-)-Camphanic acid and hex-5-en-1-ol. TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.77 (ddt, *J* = 16.9, 10.2, 6.7 Hz, 1H), 5.00 (dd, *J* = 17.1, 1.3 Hz, 1H), 4.95 (d, *J* = 10.2 Hz, 1H), 4.22 (td, *J* = 6.6, 2.9 Hz, 2H), 2.47 – 2.32 (m, 1H), 2.07 (q, *J* = 7.1 Hz, 2H), 2.04 – 1.96 (m, 1H), 1.91 (ddd, *J* = 13.6, 10.9, 4.6 Hz, 1H), 1.84 – 1.57 (m, 3H), 1.50 – 1.39 (m, 2H), 1.10 (s, 3H), 1.04 (s, 3H), 0.94 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 178.2, 167.6, 138.1, 115.1, 91.2, 65.5, 54.8, 54.1, 33.2, 30.6, 29.0, 28.0, 25.1, 16.8, 16.8, 9.7.

This matched literature characterization.<sup>3</sup>

Hex-5-en-1-yl 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate (1ai)





**1ai** was prepared according to **General Method A** from commercially available ciprofibrate and hex-5-en-1-ol.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.10 (d, *J* = 8.6 Hz, 2H), 6.80 (d, *J* = 8.7 Hz, 2H), 5.72 (ddt, *J* = 16.9, 10.2, 6.7 Hz, 1H), 5.03 – 4.91 (m, 2H), 4.15 (t, *J* = 6.6 Hz, 2H), 2.82 (dd, *J* = 10.6, 8.4 Hz, 1H), 2.00 (q, *J* = 7.2 Hz, 2H), 1.93 (dd, *J* = 10.7, 7.4 Hz, 1H), 1.86 – 1.67 (m, 1H), 1.65 – 1.53 (m, 2H), 1.60 (s, 6H), 1.33 (dq, *J* = 15.1, 7.6 Hz, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 174.3, 155.0, 138.2, 129.6, 128.0, 118.5, 114.9, 79.2, 65.4, 60.9, 60.4, 34.8, 33.2, 27.8, 25.8, 25.5, 25.0.

This matched literature characterization.<sup>2</sup>

### Method B:(For compounds 1q, 1ad)



According to the reported procedure,<sup>2</sup> a flame-dried round-bottomed flask was charged with aryl phenol (5.0 mmol, 1.0 equiv), allyl bromide (10 mmol, 2.0 equiv), K2CO3 (2.07 g, 15.0 mmol, 3.0 equiv), and dry MeCN (20.0 mL, 0.25 M). The reaction mixture was allowed to heat to 60 °C, stirred for 16 hours at this temperature, filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to afford the desired product.

1-(Allyloxy)-4-bromobenzene (1q)

**1q** was prepared according to **General Method B** from commercially available 4bromophenol and 3-bromoprop-1-ene.

TLC Rf = 0.90 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.37 (d, *J* = 9.0 Hz, 2H), 6.80 (d, *J* = 9.0 Hz, 2H), 6.03 (ddd, *J* = 22.5, 10.5, 5.3 Hz, 1H), 5.40 (dd, *J* = 17.3, 1.4 Hz, 1H), 5.30 (dd, *J* = 10.5, 1.2 Hz, 1H), 4.51 (d, *J* = 5.3 Hz, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 157.7, 132.9, 132.3, 117.9, 116.6, 113.0, 69.0.

This matched literature characterization.<sup>2</sup>

# (*8R*,9*S*,13*S*,14*S*)-3-(Allyloxy)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17Hcyclopenta[*a*]phenanthren-17-one (1ad)





**1ad** was prepared according to **General Method B** from commercially available estrone and 3-bromoprop-1-ene.

TLC Rf = 0.70 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.19 (d, *J* = 8.6 Hz, 1H), 6.73 (dd, *J* = 8.6, 2.7 Hz, 1H), 6.66 (d, *J* = 2.7 Hz, 1H), 6.05 (ddt, *J* = 17.2, 10.5, 5.3 Hz, 1H), 5.41 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.27 (dd, *J* = 10.5, 1.4 Hz, 1H), 4.51 (dt, *J* = 5.3, 1.4 Hz, 2H), 3.03 – 2.74 (m, 2H), 2.50 (dd, *J* = 19.1, 8.5 Hz, 1H), 2.42 – 2.32 (m, 1H), 2.25 (td, *J* = 10.8, 4.2 Hz, 1H), 2.19 – 2.09 (m, 1H), 2.08 – 2.03 (m, 1H), 2.02 – 1.97 (m, 1H), 1.97 – 1.82 (m, 1H), 1.76 – 1.35 (m, 6H), 0.91 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  156.6, 137.7, 133.5, 132.2, 126.3, 117.5, 114.8, 112.3, 68.8, 50.4, 48.0, 44.0, 38.4, 35.9, 31.6, 29.7, 26.6, 25.9, 21.6, 13.9.

This matched literature characterization.<sup>2</sup>

Method C:(For compounds 1w)



According to the reported procedure,<sup>5</sup> a flame-dried was charged with phenyl isocyanate (2.5 mmol, 1 equiv), dry DCM (5 mL), Et<sub>3</sub>N (7.5 mmol, 1.1 equiv) and alcohol (2.5 mmol, 1 equiv). The reaction mixture was stirred at room temperature until the alcohol was fully consumed (monitored by TLC). The reaction mixture was washed with 1 M HCl, water and brine and then dried with Na<sub>2</sub>SO<sub>4</sub>. Then, the organic phase was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to afford the desired product.

### 3-Methylbut-2-en-1-yl p-tolylcarbamate (1w)



**1w** was prepared according to **General Method C** from commercially available 1-isocyanato-4-methylbenzene and 3-methylbut-2-en-1-ol.

TLC Rf = 0.40 (Hexane/EtOAc = 10:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.25 (d, *J* = 9.7 Hz, 2H), 7.10 (d, *J* = 8.3 Hz, 2H), 6.51 (s, 1H), 5.39 (t, *J* = 7.2 Hz, 1H), 4.65 (d, *J* = 7.2 Hz, 2H), 2.30 (s, 3H), 1.78 (s, 3H), 1.74 (s, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  139.4, 135.4, 133.0, 129.6, 118.8, 61.9, 25.8, 20.8, 18.1. This matched literature characterization.<sup>5</sup>

## List of trifluoromethyl alkenes 3



### Method D:(For compounds 3a-3o)



According to the reported procedure,<sup>6</sup> to a 100 mL Schlenk tube equipped a magnetic stir bar, boronic acid (5.0 mmol, 1.0 equiv), and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (63.2 mg, 3 mol%) were added. The vessel was evacuated and filled with argon (three times), and then THF (20 mL) and aqueous  $K_2CO_3$  (2.0 M, 10 mL, 4.0 equiv) were added. After the addition of 2-bromo-3,3,3-trifluoropropene (1.04 mL, 10 mmol, 2.0 equiv), the reaction mixture was stirred at 60 °C overnight under an argon atmosphere. The resultant mixture was cooled to room temperature, quenched with saturated aqueous NH<sub>4</sub>Cl, and extracted with EtOAc (3 × 15 mL). The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated

under reduced pressure. The residue was purified by column chromatography on silica gel (Hexane/EtOAc) to give the desired trifluoromethyl alkene.

Procedure E: (For compounds 3p)



According to the reported procedure,<sup>7</sup> Cul (57.2 mg, 10 mol%) and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (105.3 mg, 5 mol%) were dissolved in Et<sub>3</sub>N (30 mL) under argon at room temperature. To the solution were added 2-bromo-3,3,3-trifluoroprop-1-ene (0.62 mL, 6.0 mmol, 2.0 equiv) and phenylacetylene (0.33 mL, 3.0 mmol, 1.0 equiv). The reaction mixture was left to stir at room temperature for 12 hours. The resultant mixture was diluted with saturated aqueous NH<sub>4</sub>Cl (20 mL) followed by extraction with CH<sub>2</sub>Cl<sub>2</sub> (3 X 20 mL). The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (Hexane/EtOAc = 100 : 1) to give the desired enyne **3p**.

Method E:(For compounds 3q-3r)



According to the reported procedure,<sup>8</sup> to a mixture of acid (5.0 mmol, 1.0 equiv) and oxalyl chloride (0.847 mL, 10 mmol, 2.0 equiv) in dry CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added dropwise DMF (39  $\mu$ L, 10 mol%). The reaction mixture was stirred at room temperature for 6 hours. Removal of the solvent *in vacuo* afforded the desired acid chloride which was used in the next step without further purification.

To a mixture of 3-(3,3,3-trifluoroprop-1-en-2-yl)aniline (0.94 g, 5.0 mmol, 1.0 equiv) and  $K_2CO_3$  (0.69 g, 5.0 mmol, 1.0 equiv) in dry THF (10 mL) was added dropwise a solution of the freshly prepared acid chloride (5.0 mmol, 1.0 equiv) in dry THF (10 mL). This mixture was stirred at room temperature for 6 hours before water was added to quench the reaction. The resultant mixture was extracted with EtOAc (3 X 20 mL). The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The

resultant crude product was purified by column chromatography on silica gel (Hexane/EtOAc) to give the desired trifluoromethyl alkene.

# 3. Standard Reaction Conditions:



To an oven-dried 4 mL reaction vial equipped with a stir bar was added MesAcrMe<sup>+</sup>(ClO<sub>4</sub>)<sup>-</sup> (0.8 mg, 0.002 mmol, 2 mol%), NaSO<sub>2</sub>CF<sub>3</sub> (46.8 mg, 0.30 mmol, 3.0 equiv), and K<sub>3</sub>PO<sub>4</sub> (42.4 mg, 0.20 mmol, 2.0 equiv). The vial was then charged with the alkene **1** (0.30 mmol, 3.0 equiv) and CF<sub>3</sub> alkene **3** (0.10 mmol, 1.0 equiv) in anhyd MeCN (1 mL) *via* a syringe. The cap was sealed with Parafilm®, and the solution was irradiated with a 30 W blue LED light at room temperature for 24 hours. The temperature of the reaction was maintained at approximately 27 °C *via* a fan. The solution was stirred vigorously while being irradiated. Once judged to be complete, the solution was transferred to a separatory funnel and diluted with deionized H<sub>2</sub>O (20 mL) and Et<sub>2</sub>O (20 mL). The layers were separated, and the aq layer was extracted with Et<sub>2</sub>O (3 X 20 mL). The combined organic layers were washed with deionized H<sub>2</sub>O (2 X 50 mL) followed by brine (100 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed *in vacuo* by rotary evaporation. Further purification was accomplished by SiO<sub>2</sub> column chromatography (gradient Hexane/EtOAc) to give the desired product.



Figure S1. Blue LED reactors

# 4. Characterization Data of Products:

1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4a)



**4a** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4a** (31.1 mg, 84% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.26 (t, *J* = 7.4 Hz, 2H), 7.21 (t, *J* = 7.3 Hz, 1H), 7.08 (dd, *J* = 8.7, 1.0 Hz, 2H), 7.00 (d, *J* = 7.1 Hz, 2H), 6.87 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 2.67 (dd, *J* = 13.8, 7.0 Hz, 1H), 2.61 (dd, *J* = 13.8, 7.2 Hz, 1H), 2.49 (ddd, *J* = 14.5, 5.7, 3.6 Hz, 1H), 2.39 (ddd, *J* = 14.6, 5.7, 3.6 Hz, 1H), 2.01 (dtt, *J* = 33.3, 13.3, 6.6 Hz, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.9, 154.0 (dd, J = 290.2, 286.3 Hz), 139.0, 129.3 (t, J = 2.7 Hz), 129.1, 128.5, 127.1 (q, J = 277.6 Hz), 126.4, 124.6 – 124.5 (m), 114.1, 90.0 (dd, J = 21.1, 14.2 Hz), 55.3, 39.7, 36.5 (q, J = 27.6 Hz), 32.6, 31.5.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.78 (t, *J* = 11.6 Hz, 3F), -91.19 (d, *J* = 44.7 Hz, 1F), -91.57 (d, *J* = 44.7 Hz, 3F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>19</sub>F<sub>5</sub>ONa 393.1248; found 393.1257.

## 1-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)naphthalene (4b)



4b

**4b** was prepared according to the general procedure from 1-allylnaphthalene **1b** (50.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4b** (31.5 mg, 75% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.83 (d, *J* = 8.2 Hz, 1H), 7.74 (d, *J* = 8.2 Hz, 1H), 7.51 (d, *J* = 8.5 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 1H), 7.41 – 7.33 (m, 1H), 7.28 (t, *J* = 7.6 Hz, 1H), 7.20 (d, *J* = 6.9 Hz, 1H), 7.04 (d, *J* = 8.0 Hz, 2H), 6.79 (d, *J* = 8.7 Hz, 2H), 3.80 (s, 3H), 3.18 (dd, *J* = 14.0, 6.9

Hz, 1H), 2.98 (dd, *J* = 14.0, 8.3 Hz, 1H), 2.74 – 2.57 (m, 1H), 2.42 (dd, *J* = 14.6, 7.6 Hz, 1H), 2.23 (dt, *J* = 14.2, 7.1 Hz, 1H), 2.17 – 1.88 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  158.8, 154.0 (dd, *J* = 290.8, 285.9 Hz), 135.1, 134.0, 131.8, 129.2 (t, *J* = 3.2 Hz), 128.8, 127.7, 127.4, 127.1 (d, *J* = 277.2 Hz), 125.9, 125.6, 125.2, 124.2 (t, *J* = 3.4 Hz), 123.5, 114.0, 89.9 (dd, *J* = 21.1, 13.9 Hz), 55.3, 39.1 – 35.2 (m), 31.6, 31.5, 29.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.48 (t, J = 11.9 Hz, 3F), -90.90 (d, J = 44.8 Hz, 1F), -91.19 (d, J = 44.6 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>24</sub>H<sub>21</sub>F<sub>5</sub>ONa 443.1405; found 443.1412.

### 1-methoxy-4-(1,1,6,6,6-pentafluoro-4-phenethylhex-1-en-2-yl)benzene (4c)



4c

**4c** was prepared according to the general procedure from but-3-en-1-ylbenzene **1c** (39.6 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4c** (30.2 mg, 79% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.25 (t, *J* = 7.5 Hz, 2H), 7.17 (dd, *J* = 17.9, 7.7 Hz, 3H), 7.07 (d, *J* = 7.2 Hz, 2H), 6.88 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 2.68 – 2.34 (m, 4H), 2.29 – 1.99 (m, 2H), 1.79 (dt, *J* = 13.0, 6.5 Hz, 1H), 1.68 (dd, *J* = 14.8, 7.5 Hz, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.9, 154.0 (dd, J = 289.7, 286.3 Hz), 141.5, 129.4 (t, J = 2.6 Hz), 128.4, 128.3, 127.1 (q, J = 277.6 Hz), 126.0, 125.1 – 124.4 (m), 114.1, 90.1 (dd, J = 21.4, 14.5 Hz), 55.3, 36.9 (q, J = 27.4 Hz), 34.7, 32.2, 31.9, 30.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.13 (t, J = 11.9 Hz, 3F), -91.31 (d, J = 44.9 Hz, 1F), -91.67 (d, J = 44.9 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>21</sub>H<sub>21</sub>F<sub>5</sub>ONa 407.1405; found 407.1413.

### 1-(1,1-difluoro-4-(2,2,2-trifluoroethyl)tetradec-1-en-2-yl)-4-methoxybenzene (4d)



4d

**4d** was prepared according to the general procedure from dodec-1-ene **1d** (50.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4d** (23.1 mg, 55% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.20 (d, *J* = 8.0 Hz, 2 H), 6.90 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 2.61 - 2.29 (m, 2H), 2.14 - 1.85 (m, 2H), 1.70 (dt, *J* = 13.1, 6.6 Hz, 1H), 1.42 - 1.07 (m, 18H), 0.88 (t, *J* = 7.0 Hz, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 154.0 (dd, *J* = 289.9, 286.1 Hz), 129.3 (t, *J* = 2.6 Hz), 127.2 (d, *J* = 277.1 Hz), 125.4 – 124.6 (m), 114.0, 90.2 (dd, *J* = 21.6, 14.1 Hz), 55.2, 36.9 (q, *J* = 27.1 Hz), 32.8, 32.0, 31.9, 30.5, 29.6, 29.5, 29.3, 25.7, 22.7, 14.1.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.23 (t, J = 12.5 Hz, 3F), -91.61 (d, J = 45.3 Hz, 1F), -91.93 (d, J = 46.4 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>33</sub>F<sub>5</sub>ONa 443.2344; found 443.2352.

## 1-(4-(2-bromoethyl)-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4e)

### Br 4e CF<sub>2</sub> PMP CF<sub>3</sub>

**4e** was prepared according to the general procedure from 4-bromobut-1-ene **1e** (40.2 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4e** (27.8 mg, 72% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.21 (d, *J* = 7.8 Hz, 2H), 6.91 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 3.46 - 3.24 (m, 2H), 2.47 (d, *J* = 5.4 Hz, 2H), 2.17 - 2.07 (m, 2H), 1.98 - 1.82 (m, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  159.0, 154.1 (dd, *J* = 290.2, 286.8 Hz), 129.4 (t, *J* = 3.0 Hz), 126.8 (q, *J* = 277.5 Hz), 124.6 – 124.2 (m), 114.2, 89.7 (dd, *J* = 21.1, 14.6 Hz), 55.3, 36.6 (q, *J* = 28.0 Hz), 36.1, 31.6, 29.9, 29.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.97 (t, *J* = 12.3 Hz, 3F), -90.75 (d, *J* = 43.8 Hz, 1F), -91.27 (d, *J* = 44.4 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>16</sub>BrF<sub>5</sub>ONa 409.0200; found 409.0211.

## 1-(7-bromo-1,1-difluoro-4-(2,2,2-trifluoroethyl)hept-1-en-2-yl)-4-methoxybenzene (4f)



**4f** was prepared according to the general procedure from 5-bromopent-1-ene **1f** (44.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4f** (33.2 mg, 83% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.21 (d, *J* = 8.5 Hz, 2H), 6.91 (d, *J* = 8.7 Hz, 2H), 3.82 (s, 3H), 3.56 - 2.97 (m, 2H), 2.66 - 2.44 (m, 1H), 2.40 (dd, *J* = 14.5, 7.6 Hz, 1H), 2.15 - 1.97 (m, 2H), 1.94 - 1.76 (m, 2H), 1.76 - 1.69 (m, 1H), 1.54 - 1.38 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  159.0, 154.1 (dd, *J* = 290.0, 286.8 Hz), 129.3 (t, *J* = 2.6 Hz), 127.0 (d, *J* = 277.6 Hz), 124.8 – 124.6 (m), 114.2, 89.9 (dd, *J* = 21.4, 14.5 Hz), 55.3, 37.0 (q, *J* = 27.5 Hz), 33.2, 32.0, 31.4, 30.1, 29.1.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.31 (t, J = 12.0 Hz, 3F), -91.16 (d, J = 44.6 Hz, 1F), -91.51 (d, J = 44.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>16</sub>H<sub>18</sub>BrF<sub>5</sub>ONa 423.0353; found 423.0359.

### 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl benzoate (4g)





**4g** was prepared according to the general procedure from hex-5-en-1-yl benzoate **1g** (61.2 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4g** (31.4 mg, 69% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.11 – 7.84 (m, 2H), 7.56 (t, *J* = 7.4 Hz, 1H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 6.88 (d, *J* = 8.8 Hz, 2H), 4.28 (t, *J* = 6.5 Hz, 2H), 3.80 (s, 3H), 2.54 – 2.28 (m, 2H), 2.04 (qd, *J* = 11.4, 6.3 Hz, 2H), 1.81 – 1.71 (m, 2H), 1.69 (dt, *J* = 13.5, 6.7 Hz, 2H), 1.52 – 1.40 (m, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 166.6, 158.9, 154.0 (dd, J = 289.9, 286.4 Hz), 132.9, 130.4, 129.5, 129.3 (t, J = 2.6 Hz), 128.4, 127.1 (d, J = 277.3 Hz), 124.9 – 124.8 (m), 114.1, 90.1 (dd, J = 21.1, 14.3 Hz), 64.7, 55.2, 36.9 (q, J = 27.2 Hz), 32.5, 31.9, 30.5, 28.7, 22.4.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -63.23 (t, *J* = 12.6 Hz, 3F), -91.36 (d, *J* = 44.9 Hz, 1F), -91.76 (d, *J* = 44.9 Hz, 1F).

HRMS (ESI) m/z: [M+Na]<sup>+</sup> Calcd for C<sub>24</sub>H<sub>25</sub>F<sub>5</sub>O<sub>3</sub>Na 479.1616; found 479.1608.

1-(4-cyclohexyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4h)

CF<sub>2</sub> PMF CF<sub>3</sub>

4h

**4h** was prepared according to the general procedure from vinylcyclohexane **1h** (33.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4h** (31.1 mg, 86% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.20 (d, *J* = 7.9 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 2.46 (dd, *J* = 14.5, 7.6 Hz, 1H), 2.39 (ddd, *J* = 9.8, 6.1, 2.2 Hz, 1H), 2.24 – 2.02 (m, 1H), 1.97 – 1.81 (m, 1H), 1.74 (d, *J* = 13.1 Hz, 2H), 1.67 (d, *J* = 12.6 Hz, 1H), 1.53 (d, *J* = 12.4 Hz, 1H), 1.44 (dd, *J* = 19.8, 7.6 Hz, 2H), 1.25 – 0.86 (m, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  158.8, 154.0 (dd, *J* = 289.6, 285.9 Hz), 129.3 (t, *J* = 2.7 Hz), 127.5 (d, *J* = 277.0 Hz), 124.9 - 124.8 (m), 114.0, 90.4 (dd, *J* = 21.4, 13.8 Hz), 55.2, 39.1, 35.5, 34.1 (q, *J* = 27.4 Hz), 29.3, 29.0, 28.3, 26.6.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.59 (t, J = 12.6 Hz, 3F), -91.57 (d, J = 45.9 Hz, 1F), -92.34 (d, J = 45.3 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>23</sub>F<sub>5</sub>ONa 385.1561; found 385.1567.

## 3-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)hex-5-en-3-yl)-7-oxabicyclo[4.1.0]heptane (4i)



4i

**4i** was prepared according to the general procedure from 3-vinyl-7-oxabicyclo[4.1.0]heptane **1i** (37.2 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4i** (27.7 mg, 74% yield, dr = 1.6:1) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.19 (d, *J* = 7.7 Hz, 2H), 6.90 (dd, *J* = 8.8, 2.0 Hz, 2H), 3.82 (s, 3H), 3.14 (s, 2H), 2.43 (d, *J* = 6.8 Hz, 1H), 2.36 (d, *J* = 6.8 Hz, 1H), 2.17 (d, *J* = 14.4 Hz, 1H), 2.05 (ddd, *J* = 18.6, 11.2, 5.8 Hz, 1H), 1.96 – 1.81 (m, 2H), 1.78 – 1.56 (m, 2H), 1.33 – 0.93 (m, 4H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.9, 155.0 (d, *J* = 290.1 Hz), 129.4 – 129.2 (m), 127.3 (d, *J* = 276.8 Hz), 124.5, 114.1, 90.1 (dd, *J* = 21.7, 14.3 Hz), 55.3, 52.5, 51.8, 34.8 – 34.0 (m), 28.8, 26.8, 25.4, 20.5, 19.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.68 (t, J = 12.3 Hz, 3F), -91.25 (d, J = 45.1 Hz, 1F), -92.05 (d, J = 11.2 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>21</sub>F<sub>5</sub>O<sub>2</sub>Na 399.1354; found 399.1362.

### 13,13-difluoro-12-(4-methoxyphenyl)-10-(2,2,2-trifluoroethyl)tridec-12-enal (4j)



**4j** was prepared according to the general procedure from undec-10-enal **1j** (50.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4j** (35.3 mg, 84% yield) was isolated as a clear oil.

TLC Rf = 0.45 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  9.76 (s, 1H), 7.20 (d, *J* = 8.0 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 2.42 (td, *J* = 7.4, 1.9 Hz, 4H), 2.13 – 1.89 (m, 2H), 1.69 (dd, *J* = 13.0, 6.5 Hz, 1H), 1.65 – 1.52 (m, 3H), 1.36 – 1.18 (m, 11H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 202.9, 158.9, 154.0 (dd, J = 290.1, 286.3 Hz), 129.3 (t, J = 3.0 Hz), 127.2 (q, J = 277.2 Hz), 125.1 – 124.9 (m), 114.0, 90.2 (dd, J = 21.6, 14.2 Hz), 55.3, 43.9, 36.9 (q, J = 27.1 Hz), 32.8, 32.0, 30.5, 29.7, 29.5, 29.3, 29.2, 29.1, 25.6, 22.1.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.23 (t, J = 11.8 Hz, 3F), -91.55 (d, J = 45.1 Hz, 1F), -91.89 (d, J = 44.4 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>22</sub>H<sub>29</sub>F<sub>5</sub>O<sub>2</sub>Na 443.1980; found 443.1985.

# 1-(*tert*-butyl) 2-(8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl) (2R)-pyrrolidine-1,2-dicarboxylate (4k)



#### 4k

**4k** was prepared according to the general procedure from 1-(tert-butyl) 2-(hex-5-en-1-yl) (R)pyrrolidine-1,2-dicarboxylate **1k** (89.1 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4k** (42.2 mg, 77% yield, dr = 1:1) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.13 (d, *J* = 8.4 Hz, 2H), 6.83 (d, *J* = 8.8 Hz, 2H), 4.29 – 4.08 (m, 1H), 4.09 – 3.92 (m, 2H), 3.75 (s, 3H), 3.57 – 3.19 (m, 2H), 2.59 – 2.26 (m, 2H), 2.31 – 2.07 (m, 1H), 2.05 – 1.91 (m, 2H), 1.86 (ddd, *J* = 19.6, 12.6, 6.9 Hz, 2H), 1.63 (dd, *J* = 8.0, 5.3 Hz, 2H), 1.49 (dt, *J* = 14.0, 7.2 Hz, 2H), 1.38 (s, 4H), 1.33 (s, 5H), 1.32 – 1.14 (m, 4H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  173.3, 158.9, 154.1 (dd, *J* = 316.6, 257.8 Hz), 153.8, 129.3, 127.1 (d, *J* = 277.4 Hz), 124.8, 114.1, 90.0 (dd, *J* = 18.2, 10.2 Hz), 79.9, 64.6, 59.2, 55.3, 46.3, 38.6 – 35.0 (m), 32.4, 30.9, 30.5, 28.7, 28.3, 24.3, 23.6, 22.2.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.24 - -63.29 (m, 3F), -91.28 (d, J = 44.8 Hz, 1F), -91.77 (d, J = 45.1 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>27</sub>H<sub>36</sub>F<sub>5</sub>O<sub>5</sub>NNa 572.2406; found 572.2415.

### 6,6-difluoro-5-(4-methoxyphenyl)-3-(2,2,2-trifluoroethyl)hex-5-enenitrile (4I)

1	PMP
NC	CF <sub>3</sub>
	41

**4I** was prepared according to the general procedure from but-3-enenitrile **1I** (20.1 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4I** (12.8 mg, 40% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.22 (d, *J* = 8.4 Hz, 2H), 6.93 (d, *J* = 8.7 Hz, 2H), 3.82 (s, 3H), 2.75 – 2.53 (m, 2H), 2.45 (dd, *J* = 5.2, 2.4 Hz, 2H), 2.39 – 2.17 (m, 2H), 2.10 (dt, *J* = 12.6, 6.3 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  159.3, 154.3 (dd, *J* = 291.7, 288.6 Hz), 129.2 (t, *J* = 2.7 Hz), 126.1 (d, *J* = 277.0 Hz), 123.6 (t, *J* = 3.1 Hz), 116.9, 114.5, 88.8 (dd, *J* = 20.7, 16.1 Hz), 55.3, 36.4 (q, *J* = 28.7 Hz), 31.7, 28.3, 21.4.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -63.49 (t, *J* = 11.6 Hz, 3F), -89.38 (d, *J* = 40.5 Hz, 1F), -89.55 (d, *J* = 40.8 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>14</sub>F<sub>5</sub>NONa 342.0888; found 342.0880.

# *tert*-butyl (5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)carbamate (4m)



4m

**4m** was prepared according to the general procedure from *tert*-butyl allylcarbamate **1m** (47.1 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4m** (24.5 mg, 60% yield) was isolated as a clear oil.

TLC Rf = 0.30 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.22 (d, *J* = 8.3 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 4.49 (s, 1H), 3.81 (s, 3H), 3.15 (d, *J* = 5.3 Hz, 2H), 2.48 (d, *J* = 7.4 Hz, 2H), 2.30 – 2.09 (m, 1H), 2.09 – 1.95 (m, 1H), 1.91 – 1.73 (m, 1H), 1.43 (s, 9H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 159.0, 156.2, 156.0 – 151.1 (m), 129.3, 126.9 (d, *J* = 277.9 Hz), 124.5, 114.2, 89.6 (dd, *J* = 21.3, 14.7 Hz), 79.6, 55.3, 42.8, 35.2, 32.1, 30.1, 28.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.67 (t, *J* = 11.7 Hz, 3F), -89.51 (d, *J* = 42.2 Hz, 1F), -90.52 (d, *J* = 42.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>24</sub>F<sub>5</sub>NO<sub>3</sub>Na 432.1569; found 432.1577.

### 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl acetate (4n)



4n

**4n** was prepared according to the general procedure from allyl acetate **1n** (30.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4n** (22.9 mg, 65% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.22 (d, *J* = 7.9 Hz, 2H), 6.91 (d, *J* = 8.8 Hz, 2H), 4.00 (ddd, *J* = 26.0, 11.4, 4.5 Hz, 2H), 3.82 (s, 3H), 2.54 (dd, *J* = 7.2, 2.0 Hz, 2H), 2.38 – 2.20 (m, 1H), 2.15 – 2.08 (m, 1H), 2.05 (s, 3H), 2.06 – 1.99 (m, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  170.8, 159.1, 154.1 (dd, *J* = 290.6, 287.1 Hz), 129.3 (t, *J* = 2.7 Hz), 126.7 (q, *J* = 277.0 Hz), 124.3 (t, *J* = 3.3 Hz), 114.2, 89.3 (dd, *J* = 21.0, 15.1 Hz), 64.7, 55.3, 34.9 (q, *J* = 28.4 Hz), 30.5, 29.4, 20.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.65 (t, J = 10.9 Hz, 3F), -89.84 (d, J = 41.4 Hz, 1F), -90.10 (d, J = 41.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>16</sub>H<sub>17</sub>F<sub>5</sub>O<sub>3</sub>Na 375.0990; found 375.0997.

### 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl hexanoate (40)



**4o** was prepared according to the general procedure from allyl hexanoate **1o** (46.8 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4o** (29.0 mg, 71% yield) was isolated as a clear oil.

TLC Rf = 0.60 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.22 (d, *J* = 8.0 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 4.00 (qd, *J* = 11.4, 4.4 Hz, 2H), 3.82 (s, 3H), 2.53 (d, *J* = 7.3 Hz, 2H), 2.30 (t, *J* = 7.6 Hz, 2H), 2.20 (s, 1H), 2.12 (ddd, *J* = 26.3, 16.1, 10.5 Hz, 1H), 2.05 (dt, *J* = 10.7, 3.8 Hz, 1H), 1.61 (dt, *J* = 14.9, 7.6 Hz, 2H), 1.44 – 1.19 (m, 4H), 0.90 (t, *J* = 7.0 Hz, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 173.6, 159.0, 154.1 (dd, J = 290.7, 287.3 Hz), 129.3 (t, J = 2.7 Hz), 126.7 (d, J = 277.0 Hz), 124.3 (t, J = 3.5 Hz), 114.2, 89.3 (dd, J = 21.3, 14.9 Hz), 64.5, 55.3, 34.9 (q, J = 28.4 Hz), 34.1, 31.3, 30.6, 29.5, 24.6, 22.3, 13.9.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.65 (t, J = 10.8 Hz, 3F), -90.25 (d, J = 42.0 Hz, 1F), -90.72 (d, J = 41.9 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>25</sub>F<sub>5</sub>O<sub>3</sub>Na 431.1616; found 431.1624.

# 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl 2-phenoxyacetate (4p)



**4p** was prepared according to the general procedure from allyl 2-phenoxyacetate **1p** (57.6 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4p** (22.2 mg, 50% yield) was isolated as a clear oil.

TLC Rf = 0.60 (Hexane/EtOAc = 20:1, v/v).

1H NMR (600 MHz, CDCl3) δ 7.31 (t, J = 7.9 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 7.01 (t, J = 7.4 Hz, 1H), 6.95 – 6.82 (m, 4H), 4.65 (s, 2H), 4.25 – 3.99 (m, 2H), 3.81 (s, 3H), 2.58 – 2.30 (m, 2H), 2.16 – 1.83 (m, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 168.9, 159.1, 157.7, 154.1 (dd, J = 290.9, 287.4 Hz), 129.7, 129.3 (t, J = 3.0 Hz), 126.5 (d, J = 276.9 Hz), 124.6 – 123.9(m), 121.9 114.5, 114.3, 89.2 (dd, J = 20.9, 15.2 Hz), 65.5, 65.0, 55.3, 34.6 (q, J = 28.5 Hz), 30.5, 29.4.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.68 (t, J = 10.8 Hz, 3F), -90.28 (d, J = 42.0 Hz, 1F), -90.75 (d, J = 41.9 Hz, 1F).

HRMS (ESI) m/z: [M+Na]<sup>+</sup> Calcd for C<sub>22</sub>H<sub>21</sub>F<sub>5</sub>O<sub>4</sub>Na 467.1252; found 467.1264.

### 1-bromo-4-((5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1yl)oxy)benzene (4q)



4q

**4q** was prepared according to the general procedure from 1-(allyloxy)-4-bromobenzene **1q** (63.3 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4q** (28.8 mg, 62% yield) was isolated as a clear oil. TLC R*f* = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.35 (d, *J* = 8.6 Hz, 2H), 7.21 (d, *J* = 8.4 Hz, 2H), 6.87 (d, *J* = 8.5 Hz, 2H), 6.69 (d, *J* = 8.6 Hz, 2H), 3.89 – 3.76 (m, 2H), 3.80 (s, 3H), 2.73 – 2.62 (m, 2H), 2.39 (qd, *J* = 17.8, 8.5 Hz, 1H), 2.26 – 2.10 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 159.0, 157.6, 154.1 (dd, J = 290.8, 287.7 Hz), 132.3, 129.2 (t, J = 3.0 Hz), 126.9 (d, J = 277.0 Hz), 124.5 (t, J = 3.4 Hz), 116.3, 114.2, 113.3, 89.5 (dd, J = 21.0, 14.9 Hz), 68.3, 55.3, 34.7 (q, J = 28.4 Hz), 31.4, 29.4.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -63.59 (t, *J* = 12.2 Hz, 3F), -90.50 (d, *J* = 42.7 Hz, 1F), -90.76 (d, *J* = 42.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>18</sub>BrF<sub>5</sub>O<sub>2</sub>Na 487.0302; found 487.0314.

### 1-(1,1-difluoro-3-(2-(trifluoromethyl)cyclopentyl)prop-1-en-2-yl)-4-methoxybenzene (4r)



**4r** was prepared according to the general procedure from cyclopentene **1r** (20.1 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4r** (25.9 mg, 81% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.23 (d, *J* = 7.9 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 2.65 (ddt, *J* = 14.1, 5.4, 3.5 Hz, 1H), 2.34 (ddd, *J* = 14.2, 9.8, 2.3 Hz, 1H), 2.25 (ddt, *J* = 13.3, 9.9, 5.0 Hz, 1H), 2.11 – 2.01 (m, 1H), 1.93 – 1.83 (m, 1H), 1.79 – 1.68 (m, 2H), 1.64 (dt, *J* = 12.7, 6.3 Hz, 1H), 1.56 (dt, *J* = 13.0, 7.4 Hz, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  158.8, 154.0 (dd, *J* = 289.9, 285.6 Hz), 129.3 (t, *J* = 3.2 Hz), 128.6 (q, *J* = 277.7 Hz), 125.1 (t, *J* = 3.3 Hz), 114.0, 90.8 (dd, *J* = 21.5, 13.8 Hz), 55.3, 48.1 (q, *J* = 26.1 Hz), 38.5, 33.2, 32.3, 26.7 (d, *J* = 2.1 Hz), 24.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -70.40 (d, *J* = 10.6 Hz, 3F), -92.04 (d, *J* = 46.6 Hz, 1F), -92.35 (dd, *J* = 45.3, 4.1 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>16</sub>H<sub>17</sub>F<sub>5</sub>ONa 343.1092; found 343.1099.

### 1-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-2-(trifluoromethyl)cyclooctane (4s)

 $CF_2$ PMP  $CF_3$ 4s

**4s** was prepared according to the general procedure from (Z)-cyclooctene **1s** (33.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-

methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4s** (31.5 mg, 87% yield, dr = 1.2:1) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.20 (d, *J* = 8.4 Hz, 2H), 6.89 (d, *J* = 7.3 Hz, 2H), 3.82 (s, 3H), 2.27 (dd, *J* = 18.1, 5.9 Hz, 2H), 2.12 (ddd, *J* = 19.0, 16.9, 9.5 Hz, 1H), 2.00 - 1.67 (m, 4H), 1.67 - 1.55 (m, 2H), 1.53 - 1.29 (m, 7H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  158.7, 154.0 (dd, *J* = 303.1, 287.4 Hz), 129.4 (t, *J* = 3.0 Hz), 128.7 (d, *J* = 279.8 Hz), 125.7 (d, *J* = 10.9 Hz), 113.9, 90.8 (dd, *J* = 19.6, 15.6 Hz), 55.3, 42.7 (q, *J* = 24.2 Hz), 35.6, 35.1, 31.7, 29.1, 26.1, 25.2, 24.6, 23.9.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -73.25 (d, *J* = 10.9 Hz, 1.5F), -73.38 (d, *J* = 10.9 Hz, 1.5F), -92.36 (d, *J* = 18.1 Hz, 2F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>23</sub>F<sub>5</sub>ONa 385.1561; found 385.1564.

### 2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-3-(trifluoromethyl)bicyclo[2.2.1]heptane (4t)



**4t** was prepared according to the general procedure from (1R,4S)-bicyclo[2.2.1]hept-2-ene **1t** (28.2 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4t** (29.7 mg, 86% yield, dr = 1.7:1) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.25 – 7.08 (m, 2H), 6.98 – 6.84 (m, 2H), 3.82 (s, 3H), 2.68 – 2.33 (m, 4H), 2.17 – 2.01 (m, 2H), 1.94 – 1.65 (m, 2H), 1.65 – 1.55 (m, 1H), 1.51 – 1.30 (m, 1H), 1.25 – 1.16 (m, 1H), 1.12 (d, *J* = 10.7 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.8, 153.8 (dd, J = 255.6, 252.8 Hz), 129.5 (t, J = 3.1 Hz), 127.8 (d, J = 280.1 Hz), 125.4 – 125.2 (m), 114.0, 91.4 (dd, J = 21.6, 14.3 Hz), 55.3, 49.5 (q, J = 24.9 Hz), 42.8, 39.5, 38.6, 34.1, 29.9, 28.5, 21.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.95 (t, J = 11.7 Hz, 3F), -90.71 (d, J = 43.8 Hz, 1F), -91.24 (d, J = 44.1 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>19</sub>F<sub>5</sub>ONa 369.1248; found 369.1240.

### 1-(4-ethyl-1,1-difluoro-5-(trifluoromethyl)hept-1-en-2-yl)-4-methoxybenzene (4u)



**4u** was prepared according to the general procedure from(E)-hex-3-ene **1u** (25.2 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4u** (13.4 mg, 40% yield, dr = 2:1) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.24 – 7.04 (m, 2H), 6.93 – 6.83 (m, 2H), 3.82 (s, 3H), 2.60 – 2.41 (m, 1H), 2.41 – 2.23 (m, 1H), 2.21 – 1.88 (m, 1H), 1.57 – 1.10 (m, 5H), 0.91 (t, *J* = 7.5 Hz, 3H), 0.85 (t, *J* = 7.3 Hz, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 157.9 – 153.5 (m), 129.4 (t, *J* = 2.6 Hz), 128.8 (d, *J* = 282.1 Hz), 125.3 – 124.8 (m), 114.0, 90.7 (dd, *J* = 21.6, 14.2 Hz), 55.3, 45.1 (dd, *J* = 47.6, 23.9 Hz), 36.9, 28.9, 22.6, 17.7, 12.9, 12.0.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>):

For major:  $\delta$  -65.88 (d, J = 11.8 Hz, 2F), -91.52 (d, J = 45.8 Hz, 0.66F), -92.54 (d, J = 45.5 Hz, 0.66F).

For minor:  $\delta$  -65.46 (d, J = 12.0 Hz, 1F), -91.65 (d, J = 44.5 Hz, 0.33F), -92.05 (d, J = 45.8 Hz, 0.33F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>21</sub>F<sub>5</sub>ONa 359.1405; found 359.1411.

# 6,6-difluoro-5-(4-methoxyphenyl)-3-methyl-3-(2,2,2-trifluoroethyl)hex-5-en-1-yl benzoate (4v)



**4v** was prepared according to the general procedure from 3-methylbut-3-en-1-yl benzoate **1v** (57.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4v** (36.2 mg, 82% yield) was isolated as a clear oil. TLC R*f* = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.98 (d, *J* = 7.3 Hz, 2H), 7.56 (t, *J* = 7.4 Hz, 1H), 7.44 (t, *J* = 7.7 Hz, 2H), 7.22 (d, *J* = 8.1 Hz, 2H), 6.87 (d, *J* = 8.7 Hz, 2H), 4.28 (dd, *J* = 10.4, 4.3 Hz, 2H), 3.74 (s, 3H), 2.57 (q, *J* = 14.5 Hz, 2H), 2.25 – 1.95 (m, 2H), 1.92 – 1.75 (m, 2H), 1.00 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  166.5, 158.9, 157.0 – 152.4 (m), 133.0, 130.2, 130.1, 129.5, 128.4, 126.9 (dd, *J* = 590.0, 311.4 Hz), 126.5 (dd, *J* = 4.1, 2.0 Hz), 114.1, 89.0 (dd, *J* = 20.7, 15.3 Hz), 61.2, 55.2, 42.1 (q, *J* = 26.4 Hz), 38.2, 37.4, 36.0, 24.9.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -58.76 (t, *J* = 12.6 Hz, 3F), -89.07 (d, *J* = 40.6 Hz, 1F), -90.77 (d, *J* = 40.3 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>23</sub>F<sub>5</sub>O<sub>3</sub>Na 465.1460; found 465.1472.

### 6,6-difluoro-5-(4-methoxyphenyl)-3,3-dimethyl-2-(trifluoromethyl)hex-5-en-1-yl ptolylcarbamate (4w)



**4w** was prepared according to the general procedure from 3-methylbut-2-en-1-yl p-tolylcarbamate **1w** (65.7 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4w** (36.7 mg, 78% yield) was isolated as a white solid.

TLC Rf = 0.45 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.26 (s, 2H), 7.22 (d, *J* = 8.2 Hz, 2H), 7.12 (d, *J* = 8.3 Hz, 2H), 6.87 (d, *J* = 8.7 Hz, 2H), 6.44 (s, 1H), 4.36 (d, *J* = 11.1 Hz, 1H), 4.23 (dd, *J* = 12.0, 6.7 Hz, 1H), 3.75 (s, 3H), 2.56 (s, 2H), 2.31 (s, 3H), 2.29 – 2.15 (m, 1H), 0.98 (s, 3H), 0.95 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.8, 154.6 (t, J = 289.0 Hz), 134.9, 133.3, 129.6, 129.5, 127.7 (d, J = 258.9 Hz), 127.3, 126.6, 118.8 – 118.5 (m), 114.1, 89.2 (dd, J = 21.0, 14.8 Hz), 60.7, 55.2, 50.1 (q, J = 23.5 Hz), 38.3, 36.9, 25.7, 25.4, 20.8.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -61.84 (t, *J* = 11.6 Hz, 3F), -89.14 (d, *J* = 40.6 Hz, 1F), -91.18 (d, *J* = 40.8 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>24</sub>H<sub>26</sub>F<sub>5</sub>NO<sub>3</sub>Na 494.1725; found 494.1729.

### 1-methoxy-4-(1,1,6,6,6-pentafluoro-4,4,5,5-tetramethylhex-1-en-2-yl)benzene (4x)

F<sub>3</sub>C

**4**x

**4x** was prepared according to the general procedure from 2,3-dimethylbut-2-ene **1x** (25.2 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4x** (19.2 mg, 57% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.22 (d, *J* = 7.6 Hz, 2H), 6.88 (d, *J* = 8.7 Hz, 2H), 3.81 (s, 3H), 2.54 (s, 2H), 1.11 (s, 6H), 0.79 (s, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.5, 154.4 (dd, J = 289.5, 287.7 Hz), 130.2 (d, J = 286.6 Hz), 129.4 – 129.3 (m), 128.0 – 127.7 (m), 113.9, 89.9 (dd, J = 21.0, 14.0 Hz), 55.3, 46.2 (q, J = 21.3 Hz), 39.7, 34.4, 23.0, 18.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -68.68 (s, 3F), -89.60 (d, *J* = 42.0 Hz, 1F), -91.86 (d, *J* = 41.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>21</sub>F<sub>5</sub>ONa 359.1405; found 359.1411.

### 1-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)hex-5-en-3-yl)pyrrolidin-2-one (4y)

4y

**4y** was prepared according to the general procedure from 1-vinylpyrrolidin-2-one **1y** (33.3 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4y** (30.5 mg, 84% yield) was isolated as a clear oil.

TLC Rf = 0.35 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.21 (d, *J* = 8.5 Hz, 2H), 6.90 (d, *J* = 8.6 Hz, 2H), 4.15 (s, 1H), 3.81 (s, 3H), 3.16 (t, *J* = 7.0 Hz, 2H), 2.93 – 2.77 (m, 1H), 2.66 (dt, *J* = 15.0, 10.2 Hz, 1H), 2.60 – 2.42 (m, 1H), 2.24 (ddd, *J* = 15.0, 10.6, 4.2 Hz, 1H), 2.19 (t, *J* = 8.1 Hz, 2H), 1.81 (tt, *J* = 14.6, 7.5 Hz, 1H), 1.71 (tt, *J* = 15.3, 7.7 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 175.1, 159.1, 154.2 (dd, J = 291.1, 288.1 Hz), 129.3 (t, J = 2.6 Hz), 125.8 (q, J = 277.1 Hz), 124.5 (t, J = 3.5 Hz), 114.1, 89.0 (dd, J = 20.9, 16.1 Hz), 55.3, 46.7, 44.8, 35.0 (q, J = 28.2 Hz), 31.3, 30.6, 18.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -64.52 (t, J = 10.7 Hz, 3F), -90.33 (d, J = 41.1 Hz, 1F), -90.58 (d, J = 42.1 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>18</sub>NF<sub>5</sub>O<sub>2</sub>Na 386.1150; found 386.1157.

### 1-(4-butoxy-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4z)

MP

4z

**4z** was prepared according to the general procedure from 1-(vinyloxy)butane **1z** (30.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4z** (31.7 mg, 90% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.24 (d, *J* = 8.7 Hz, 2H), 6.91 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 3.71 - 3.43 (m, 1H), 3.35 (t, *J* = 6.5 Hz, 2H), 2.82 - 2.59 (m, 1H), 2.58 - 2.45 (m, 1H), 2.29 (tdd, *J* = 18.3, 9.2, 6.0 Hz, 1H), 2.23 - 1.99 (m, 1H), 1.53 - 1.37 (m, 2H), 1.31 (dd, *J* = 15.1, 7.5 Hz, 2H), 0.88 (t, *J* = 7.4 Hz, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 154.3 (t, *J* = 288.9 Hz), 129.3 (t, *J* = 3.1 Hz), 126.1 (q, *J* = 277.0 Hz), 125.1, 114.1, 88.7 (t, *J* = 18.2 Hz), 72.2, 69.8, 55.3, 38.6 (q, *J* = 27.5 Hz), 33.4, 31.9, 19.2, 13.8.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.48 – -63.52 (m, 3F), -90.72 (s, 2F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>21</sub>F<sub>5</sub>O<sub>2</sub>Na 375.1354; found 375.1360.

# 2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-3-(trifluoromethyl)tetrahydro-2H-pyran (4aa)

F<sub>2</sub>C ′CF<sub>3</sub>

#### 4aa

**4aa** was prepared according to the general procedure from 3,4-dihydro-2H-pyran **1aa** (25.2 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4aa** (25.2 mg, 75% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.23 (d, *J* = 8.2 Hz, 2H), 6.89 (d, *J* = 8.8 Hz, 2H), 3.98 – 3.86 (m, 1H), 3.82 (s, 3H), 3.32 – 3.18 (m, 1H), 3.15 (ddd, *J* = 11.5, 7.8, 4.8 Hz, 1H), 2.77 (dd, *J* = 14.9, 3.3 Hz, 1H), 2.54 (dd, *J* = 14.4, 11.0 Hz, 1H), 2.12 (ddd, *J* = 8.9, 8.0, 3.6 Hz, 1H), 2.09 – 2.00 (m, 1H), 1.69 – 1.53 (m, 2H), 1.51 – 1.37 (m, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.7, 154.1 (t, J = 287.2 Hz), 129.6 (t, J = 2.8 Hz), 126.6 (q, J = 279.9 Hz), 125.4 – 125.3 (m), 113.9, 88.9 (dd, J = 21.7, 16.4 Hz), 74.0, 67.7, 55.2, 44.9 (q, J = 24.8 Hz), 32.4, 24.4, 23.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -67.54 (d, *J* = 9.8 Hz, 3F), -91.37 (dd, *J* = 44.9, 5.7 Hz, 1F), -92.23 (d, *J* = 46.5 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>16</sub>H<sub>17</sub>F<sub>5</sub>O<sub>2</sub>Na 359.1041; found 359.1048.

# 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 3-(4,5-diphenyloxazol-2-yl)propanoate (4ab)



4ab

**4ab** was prepared according to the general procedure from hex-5-en-1-yl 3-(4,5diphenyloxazol-2-yl)propanoate **1ab** (112.5 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4ab** (48.3 mg, 77% yield) was isolated as a white solid.

TLC Rf = 0.50 (Hexane/EtOAc = 10:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.69 – 7.59 (m, 2H), 7.57 (dd, *J* = 5.2, 3.3 Hz, 2H), 7.43 – 7.28 (m, 6H), 7.19 (d, *J* = 8.0 Hz, 2H), 6.89 (d, *J* = 8.8 Hz, 2H), 4.23 – 3.95 (m, 2H), 3.80 (s, 3H), 3.18 (t, *J* = 7.6 Hz, 2H), 2.90 (t, *J* = 7.6 Hz, 2H), 2.46 – 2.32 (m, 2H), 2.00 (qd, *J* = 11.4, 6.3 Hz, 2H), 1.71 (dd, *J* = 12.8, 6.4 Hz, 1H), 1.57 – 1.49 (m, 2H), 1.30 (ddd, *J* = 20.2, 13.0, 5.8 Hz, 4H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  172.0, 161.8, 158.9, 154.0 (dd, *J* = 290.0, 286.5 Hz), 145.4, 135.1, 132.5, 129.3 (t, *J* = 2.9 Hz), 129.0, 128.7, 128.6, 128.5, 128.0 (d, *J* = 11.1 Hz), 127.9, 127.1 (d, *J* = 277.1 Hz), 126.5, 125.3 – 124.6 (m), 114.1, 90.1 (dd, *J* = 21.1, 14.3 Hz), 64.5, 55.3, 36.8 (q, *J* = 27.6 Hz), 32.4, 31.9, 31.2, 30.5, 29.7, 28.6, 23.6, 22.1.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -63.22 (t, *J* = 12.0 Hz, 3F), -91.33 (d, *J* = 44.8 Hz, 1F), -91.71 (d, *J* = 44.6 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>35</sub>H<sub>34</sub>F<sub>5</sub>NO<sub>4</sub>Na 650.2300; found 650.2311.

### 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4isobutylphenyl)propanoate (4ac)



4ac

4ac was prepared according to the general procedure from hex-5-en-1-yl 2-(4isobutylphenyl)propanoate 1ac (86.4 0.30 3.0 mg, mmol, equiv), sodium trifluoromethanesulfinate 2a (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3trifluoroprop-1-en-2-yl)benzene 3a (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene 4ac (43.2 mg, 80% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.23 – 7.13 (m, 4H), 7.07 (d, *J* = 7.4 Hz, 2H), 6.89 (d, *J* = 8.5 Hz, 2H), 4.01 (ddd, *J* = 9.0, 6.1, 2.7 Hz, 2H), 3.81 (s, 3H), 3.67 (q, *J* = 7.1 Hz, 1H), 2.42 (d, *J* = 7.2 Hz, 2H), 2.47 – 2.37 (m, 1H), 2.34 (dd, *J* = 14.2, 7.4 Hz, 1H), 2.08 – 1.89 (m, 2H), 1.83 (dt, *J* = 13.5, 6.7 Hz, 1H), 1.66 (dt, *J* = 13.0, 6.5 Hz, 1H), 1.53 – 1.44 (m, 5H), 1.35 – 1.23 (m, 2H), 1.24 – 1.07 (m, 2H), 0.88 (d, *J* = 6.6 Hz, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  174.8, 158.9, 154.0 (dd, *J* = 290.0, 286.6 Hz), 140.5, 137.8, 127.1, 127.1 (d, *J* = 277.3 Hz), 125.3 – 124.4 (m), 114.1, 90.1 (dd, *J* = 21.4, 14.2 Hz), 64.3, 55.3, 45.2, 45.0, 36.8 (dd, *J* = 51.4, 27.4 Hz), 32.4, 31.8, 30.4, 30.2, 28.6, 22.4, 22.0, 18.4 (d, *J* = 7.1 Hz).

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -63.24 (t, *J* = 15.6 Hz, 3F), -91.38 (d, *J* = 46.0 Hz, 1F), -91.76 (d, *J* = 45.2 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>30</sub>H<sub>37</sub>F<sub>5</sub>O<sub>3</sub>Na 563.2555; found 563.2567.

### (8R,9S,13S,14S)-3-((5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1yl)oxy)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (4ad)



#### 4ad

**4ad** was prepared according to the general procedure from (8R,9S,13S,14S)-3-(allyloxy)-13methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one **1ad** (93.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4ad** (42.1 mg, 75% yield) was isolated as a white solid. TLC R*f* = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.24 (d, *J* = 8.3 Hz, 2H), 7.19 (d, *J* = 8.6 Hz, 1H), 6.89 (d, *J* = 8.8 Hz, 2H), 6.65 (dd, *J* = 8.6, 2.6 Hz, 1H), 6.57 (d, *J* = 2.5 Hz, 1H), 3.85 (dd, *J* = 7.7, 4.7 Hz, 2H), 3.81 (s, 3H), 2.88 (dd, *J* = 11.0, 4.7 Hz, 2H), 2.78 – 2.58 (m, 2H), 2.51 (dd, *J* = 18.8, 8.5 Hz, 1H), 2.47 – 2.32 (m, 2H), 2.24 (dd, *J* = 17.8, 7.3 Hz, 2H), 2.20 – 2.11 (m, 4H), 2.10 – 1.92 (m, 2H), 1.72 – 1.48 (m, 3H), 1.49 – 1.29 (m, 2H), 0.91 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.9, 156.6, 154.1 (dd, J = 290.5, 287.5 Hz), 137.8, 132.5, 129.3 (t, J = 2.6 Hz), 127.0 (d, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 114.5, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 126.4, 114.5, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 126.4, 114.5, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 126.4, 114.5, 114.5, 114.2, 112.2, 112.1, 89.6 (dd, J = 276.9 Hz), 126.4, 126.4, 114.5, 114.5, 114.2, 114.5,

21.0, 14.9 Hz), 68.2, 55.3, 50.4, 48.0, 44.0, 38.4, 35.9, 34.6 (q, J = 28.2 Hz), 31.6, 31.4, 29.6, 29.5, 26.6, 25.9, 21.6, 13.9.
<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.53 (t, J = 12.3 Hz, 3F), -90.62 (d, J = 42.9 Hz, 1F), -90.81 (d, J = 44.5 Hz, 1F).
HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>32</sub>H<sub>35</sub>F<sub>5</sub>O<sub>3</sub>Na 585.2399; found 585.2390.

# 4-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)-1,2-dimethoxybenzene (4ae)



**4ae** was prepared according to the general procedure from 4-allyl-1,2-dimethoxybenzene **1ae** (53.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4ae** (36.1 mg, 84% yield) was isolated as a clear oil. TLC R*f* = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.10 (d, *J* = 7.9 Hz, 2H), 6.87 (d, *J* = 8.8 Hz, 2H), 6.76 (d, *J* = 8.1 Hz, 1H), 6.57 (dd, *J* = 8.1, 1.9 Hz, 1H), 6.43 (d, *J* = 1.9 Hz, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 2.67 – 2.53 (m, 2H), 2.48 (dd, *J* = 14.7, 7.2 Hz, 1H), 2.39 (dd, *J* = 14.9, 7.2 Hz, 1H), 2.04 (qd, *J* = 11.4, 6.3 Hz, 2H), 1.98 – 1.86 (m, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.9, 154.0 (dd, J = 290.1, 286.3 Hz), 148.9, 147.6, 131.6, 129.4 (t, J = 3.0 Hz), 127.1 (q, J = 277.8 Hz), 124.6 – 124.5 (m), 121.2, 114.0, 111.9, 111.1, 90.1 (dd, J = 21.1, 14.1 Hz), 55.9, 55.8, 55.3, 39.2, 36.6 (q, J = 27.6 Hz), 32.7, 31.4.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.75 (t, J = 12.6 Hz, 3F), -91.20 (d, J = 45.0 Hz, 1F), -91.63 (d, J = 45.0 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>22</sub>H<sub>23</sub>F<sub>5</sub>O<sub>3</sub>Na 453.1460; found 453.1465.

### (4R,4aS,6R)-4,4a-dimethyl-6-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)-3-methylhex-5en-3-yl)-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one (4af)



**4af** was prepared according to the general procedure from (4R,4aS,6R)-4,4a-dimethyl-6-(prop-1-en-2-yl)-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one **1af** (65.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4af** (35.2 mg, 75% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.20 (t, *J* = 7.3 Hz, 2H), 6.90 (d, *J* = 8.7 Hz, 2H), 5.70 (d, *J* = 29.5 Hz, 1H), 3.80 (s, 3H), 2.58 – 2.39 (m, 2H), 2.36 (ddd, *J* = 20.1, 8.5, 5.6 Hz, 1H), 2.28 – 2.13 (m, 3H), 2.00 – 1.89 (m, 3H), 1.91 – 1.83 (m, 1H), 1.82 – 1.58 (m, 2H), 1.19 – 1.01 (m, 2H), 1.06 – 0.85 (m, 9H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 199.5, 170.1, 158.9, 154.4 (t, J = 289.1 Hz), 129.6, 127.3 (d, J = 279.0 Hz), 127.0, 124.4, 114.1, 89.3 (dd, J = 11.9, 8.7 Hz), 60.4, 55.3, 42.0, 40.6, 39.5 (dd, J = 49.5, 27.6 Hz), 38.8, 34.7, 32.8, 27.3, 23.2, 16.7, 15.0.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -57.94 (t, J = 12.7 Hz, 3F), -89.20 (d, J = 40.9 Hz, 1F), -90.75 (d, J = 40.9 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>26</sub>H<sub>31</sub>F<sub>5</sub>O<sub>2</sub>Na 493.2136; found 493.2144.

# 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (4ag)



**4ag** was prepared according to the general procedure from hex-5-en-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate **1ag** (131.7 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4ag** (55.9 mg, 81% yield) was isolated as a white solid.

TLC Rf = 0.30 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.64 (d, *J* = 8.5 Hz, 2H), 7.46 (d, *J* = 8.5 Hz, 2H), 7.16 (d, *J* = 8.2 Hz, 2H), 6.96 (d, *J* = 2.5 Hz, 1H), 6.88 (d, *J* = 8.8 Hz, 2H), 6.85 (d, *J* = 9.0 Hz, 1H), 6.66 (dd, *J* = 9.0, 2.5 Hz, 1H), 4.06 (t, *J* = 6.5 Hz, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.65 (s, 2H), 2.39 (s, 3H), 2.43 - 2.34 (m, 1H), 2.32 (dd, *J* = 14.5, 7.4 Hz, 1H), 2.05 - 1.84 (m, 2H), 1.67 (dt, *J* = 13.1, 6.5 Hz, 1H), 1.57 - 1.45 (m, 2H), 1.37 - 1.28 (m, 2H), 1.28 - 1.14 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  170.9, 168.3, 158.9, 156.0, 154.0 (dd, *J* = 290.3, 286.1 Hz), 139.3, 136.0, 133.9, 131.2, 130.8, 130.7, 129.3 (t, *J* = 2.6 Hz), 129.1, 127.1 (d, *J* = 277.1 Hz), 124.8 (t, *J* = 3.4 Hz), 115.0, 114.1, 112.6, 111.5, 101.4, 90.1 (dd, *J* = 21.3, 14.4 Hz), 64.7, 55.7, 55.3, 36.7 (q, *J* = 27.4 Hz), 32.4, 31.7, 30.4, 28.6, 22.1, 13.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.22 (t, J = 11.9 Hz, 3F), -91.32 (d, J = 44.7 Hz, 1F), -91.70 (d, J = 44.6 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>36</sub>H<sub>35</sub>F<sub>5</sub>CINO<sub>5</sub>Na 714.2016; found 714.2028.

### 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl (1S,4R)-4,7,7trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (4ah)



**4ah** was prepared according to the general procedure from hex-5-en-1-yl (1S,4R)-4,7,7trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate **1ah** (84.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4ah** (46.3 mg, 87% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 10:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.19 (d, *J* = 8.3 Hz, 2H), 6.90 (d, *J* = 8.7 Hz, 2H), 4.24 – 4.13 (m, 2H), 3.81 (s, 3H), 2.52 – 2.31 (m, 3H), 2.02 (ddd, *J* = 14.5, 9.7, 6.6 Hz, 2H), 1.92 (ddd, *J* = 13.2, 10.8, 4.6 Hz, 1H), 1.69 (ddd, *J* = 17.6, 8.9, 4.6 Hz, 2H), 1.65 – 1.55 (m, 3H), 1.42 – 1.35 (m, 2H), 1.31 (dt, *J* = 21.0, 7.1 Hz, 2H), 1.11 (s, 3H), 1.04 (s, 3H), 0.94 (d, *J* = 2.7 Hz, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 178.2, 167.6, 158.9, 154.0 (dd, *J* = 290.1, 286.3 Hz), 129.3 (t, *J* = 2.5 Hz), 127.1 (q, *J* = 277.2 Hz), 124.9 – 124.7 (m), 114.1, 91.1, 90.0 (dd, *J* = 21.6, 14.2 Hz), 65.3, 65.3, 60.4, 55.3, 54.8, 54.1, 36.8 (q, *J* = 27.5 Hz), 32.3, 32.0, 30.6, 29.0, 28.6, 22.2, 16.8, 9.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.23 (t, J = 12.6 Hz, 3F), -91.26 (d, J = 46.8 Hz, 1F), -91.68 (d, J = 45.0 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>27</sub>H<sub>33</sub>F<sub>5</sub>O<sub>5</sub>Na 555.2140; found 555.2151.

# 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate (4ai)



**4ai** was prepared according to the general procedure from hex-5-en-1-yl 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate **1ai** (111.0 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **4ai** (51.0 mg, 82% yield) was isolated as a white solid.

TLC Rf = 0.40 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.18 (d, *J* = 8.3 Hz, 2H), 7.09 (d, *J* = 7.7 Hz, 2H), 6.89 (d, *J* = 8.7 Hz, 2H), 6.79 (d, *J* = 8.6 Hz, 2H), 4.10 (t, *J* = 6.5 Hz, 2H), 3.81 (s, 3H), 2.88 – 2.60 (m, 1H), 2.39 (dd, *J* = 14.5, 7.0 Hz, 1H), 2.33 (dd, *J* = 14.5, 7.5 Hz, 1H), 2.12 – 1.83 (m, 3H), 1.76 (td, *J* = 8.0, 2.4 Hz, 1H), 1.65 (dd, *J* = 13.1, 6.6 Hz, 1H), 1.60 (s, 6H), 1.55 – 1.42 (m, 2H), 1.39 – 1.25 (m, 2H), 1.25 – 1.06 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  174.3, 158.9, 155.0, 154.0 (dd, *J* = 290.1, 286.3 Hz), 129.6, 129.3 (t, *J* = 2.9 Hz), 128.1, 126.9 (dd, *J* = 508.0, 323.7 Hz), 124.9 – 124.7 (m), 118.4, 114.1, 90.1 (dd, *J* = 21.1, 14.2 Hz), 79.1, 65.1, 60.9, 55.3, 36.8 (q, *J* = 27.4 Hz), 34.8, 32.3, 31.8, 30.4, 28.4, 25.8, 25.4, 22.0.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -63.24 (t, J = 12.7 Hz, 3F), -91.42 (d, J = 44.9 Hz, 1F), -91.79 (d, J = 44.4 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>30</sub>H<sub>33</sub>F<sub>5</sub>Cl<sub>2</sub>O<sub>4</sub>Na 645.1568; found 645.1579.

### 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(tert-butyl)benzene (5a)



5a

**5a** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1- (*tert*-butyl)-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3b** (22.8 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5a** (32.5 mg, 82% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.34 (d, *J* = 8.5 Hz, 2H), 7.29 – 7.23 (m, 2H), 7.21 (dt, *J* = 9.4, 4.3 Hz, 1H), 7.11 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.03 – 6.93 (m, 2H), 2.68 (dd, *J* = 14.0, 6.2 Hz, 1H),
2.60 (dd, *J* = 14.0, 6.7 Hz, 1H), 2.56 – 2.48 (m, 1H), 2.48 – 2.31 (m, 1H), 2.17 – 1.93 (m, 3H), 1.33 (s, 9H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 154.1 (dd, J = 291.1, 286.7 Hz), 150.5, 139.0, 129.6 – 129.3 (m), 129.1, 128.5, 127.8 (t, J = 3.0 Hz), 126.4, 125.5, 90.3 (dd, J = 21.0, 13.8 Hz), 39.6, 36.5 (q, J = 27.5 Hz), 34. 6, 32.7, 31.4, 31.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.64 (t, *J* = 12.1 Hz, 3F), -90.38 (d, *J* = 43.0 Hz, 1F), -90.65 (d, *J* = 44.5 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>25</sub>F<sub>5</sub>Na 419.1769; found 419.1775.

1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(trifluoromethoxy)benzene (5b)



5b

**5b** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1- (trifluoromethoxy)-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3c** (25.6 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5b** (37.3 mg, 88% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.29 – 7.24 (m, 2H), 7.24 – 7.20 (m, 1H), 7.19 – 7.12 (m, 4H), 7.00 – 6.96 (m, 2H), 2.76 – 2.59 (m, 2H), 2.56 – 2.47 (m, 1H), 2.42 (ddt, *J* = 14.8, 6.9, 2.2 Hz, 1H), 2.13 – 1.99 (m, 2H), 1.94 (dt, *J* = 13.6, 6.8 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 154.2 (dd, J = 291.9, 287.8 Hz), 148.4, 138.8, 131.3 – 130.9 (m), 129.6 (t, J = 3.1 Hz), 129.0, 128.6, 127.0 (dd, J = 554.7, 277.1 Hz), 126.6, 121.0, 89.7 (dd, J = 21.4, 14.5 Hz), 39.8, 36.7 (q, J = 27.5 Hz), 32.7, 31.3, 29.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -57.84 (s), -62.88 (t, J = 12.3 Hz, 3F), -89.37 (d, J = 40.5 Hz, 1F), -89.50 (d, J = 40.9 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>16</sub>F<sub>8</sub>ONa 447.0966; found 447.0960.

## methyl 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzoate (5c)

 $CF_3$ MeO<sub>2</sub>C

5c

5c was prepared according to the general procedure from allylbenzene 1a (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate 2a (46.8 mg, 0.30 mmol, 3.0 equiv) and

methyl 4-(3,3,3-trifluoroprop-1-en-2-yl)benzoate **3d** (23.0 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5c** (33.0 mg, 83% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (d, *J* = 8.4 Hz, 2H), 7.29 – 7.21 (m, 5H), 6.99 (d, *J* = 6.9 Hz, 2H), 3.93 (s, 3H), 2.64 (d, *J* = 7.1 Hz, 2H), 2.60 – 2.51 (m, 1H), 2.47 (dd, *J* = 14.8, 6.9 Hz, 1H), 2.13 – 1.98 (m, 2H), 1.94 (dt, *J* = 13.5, 6.8 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 166.7, 154.4 (dd, J = 293.4, 288.7 Hz), 138.8, 137.3 (t, J = 3.7 Hz), 129.8, 129.3, 129.0, 128.6, 128.1 (t, J = 3.1 Hz), 127.1 (dd, J = 590.3, 313.0 Hz), 126.6, 90.4 (dd, J = 21.8, 13.2 Hz), 52.2, 39.8, 36.7 (q, J = 27.7 Hz), 32.8, 31.1.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.87 (t, *J* = 12.4 Hz, 3F), -88.01 (d, *J* = 37.5 Hz, 1F), -88.20 (d, *J* = 38.2 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>21</sub>H<sub>19</sub>F<sub>5</sub>O<sub>2</sub>Na 421.1197; found 421.1204.

# 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(methylsulfonyl)benzene (5d)



5d

**5d** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1- (methylsulfonyl)-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3e** (25.0 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5d** (34.3 mg, 82% yield) was isolated as a white solid.

TLC Rf = 0.30 (Hexane/EtOAc = 10:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.88 (d, *J* = 8.5 Hz, 2H), 7.36 – 7.16 (m, 5H), 7.01 (d, *J* = 7.1 Hz, 2H), 3.08 (s, 3H), 2.70 (dd, *J* = 13.9, 6.9 Hz, 1H), 2.62 (dd, *J* = 13.9, 7.6 Hz, 1H), 2.56 (dd, *J* = 15.0, 7.4 Hz, 1H), 2.52 – 2.40 (m, 1H), 2.07 (ddd, *J* = 11.5, 9.6, 6.5 Hz, 2H), 1.91 (dt, *J* = 13.7, 6.9 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 154.6 (dd, J = 294.6, 289.5 Hz), 139.5, 138.6, 138.5 – 138.3 (m), 129.0, 129.0 (t, J = 3.3 Hz), 128.7, 127.7, 126.7, 90.0 (dd, J = 22.5, 12.5 Hz), 44.5, 40.0, 36.8 (q, J = 28.0 Hz), 32.9, 31.0.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.88 (t, *J* = 11.7 Hz, 3F), -86.72 (d, *J* = 34.6 Hz, 1F), -87.07 (d, *J* = 34.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>19</sub>F<sub>5</sub>O<sub>2</sub>SNa 441.0918; found 441.0925.

# 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzonitrile (5e)



**5e** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 4- (3,3,3-trifluoroprop-1-en-2-yl)benzonitrile **3f** (19.7 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5e** (31.0 mg, 85% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.60 (d, J = 8.5 Hz, 2H), 7.33 – 7.23 (m, 3H), 7.21 (dd, J = 8.5, 1.0 Hz, 2H), 7.06 – 6.94 (m, 2H), 2.69 (dd, J = 13.8, 6.9 Hz, 1H), 2.61 (dd, J = 13.9, 7.6 Hz, 1H), 2.57 – 2.51 (m, 1H), 2.47 (ddt, J = 15.0, 6.7, 2.3 Hz, 1H), 2.18 – 1.96 (m, 2H), 1.89 (dt, J = 13.7, 6.8 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 154.5 (dd, J = 294.8, 289.5 Hz), 138.6, 137.5 – 137.4 (m), 132.4, 129.0, 128.7 (t, J = 3.3 Hz), 128.7, 126.9 (q, J = 277.0 Hz), 126.7, 118.5, 111.4, 90.1 (dd, J = 22.2, 12.9 Hz), 40.0, 36.8 (q, J = 27.8 Hz), 32.9, 30.9, 29.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.96 (t, J = 12.6 Hz, 3F), -86.79 (d, J = 34.7 Hz, 1F), -86.99 (d, J = 34.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>16</sub>F<sub>5</sub>NNa 388.1095; found 388.1104.

#### 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-bromobenzene (5f)



5f

**5f** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1-bromo-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3g** (25.0 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5f** (37.6 mg, 90% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.45 (d, *J* = 8.5 Hz, 2H), 7.28 (dd, *J* = 10.1, 4.6 Hz, 2H), 7.24 – 7.18 (m, 1H), 7.02 – 6.96 (m, 4H), 2.72 – 2.57 (m, 2H), 2.50 (dd, *J* = 14.7, 7.3 Hz, 1H), 2.41 (ddt, *J* = 14.8, 6.9, 2.2 Hz, 1H), 2.14 – 1.99 (m, 2H), 1.93 (dt, *J* = 13.6, 6.8 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 154.1 (dd, J = 292.1, 287.8 Hz), 138.8, 131.8, 131.5 – 131.1 (m), 129.7 (t, J = 3.1 Hz), 129.1, 128.6, 127.0 (q, J = 277.0 Hz), 126.6, 121.6, 89.9 (dd, J = 21.8, 14.0 Hz), 39.8, 38.0 – 35.0 (m), 32.7, 31.2, 29.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.85 (t, *J* = 12.0 Hz, 3F), -89.22 (d, *J* = 40.2 Hz, 1F), -89.44 (d, *J* = 39.2 Hz, 1F).

HRMS (ESI) m/z: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>16</sub>BrF<sub>5</sub>Na 441.0248; found 441.0243.

1-(3-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)ethan-1-one (5g)

Ac



**5g** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1- (3-(3,3,3-trifluoroprop-1-en-2-yl)phenyl)ethan-1-one **3h** (21.4 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5g** (35.5 mg, 93% yield) was isolated as a clear oil.

TLC Rf = 0.30 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.04 – 7.82 (m, 1H), 7.75 (s, 1H), 7.44 (t, *J* = 7.7 Hz, 1H), 7.35 (d, *J* = 7.7 Hz, 1H), 7.29 – 7.23 (m, 2H), 7.21 (ddd, *J* = 7.4, 3.7, 1.2 Hz, 1H), 6.99 (d, *J* = 6.9 Hz, 2H), 2.66 (dd, *J* = 6.9, 3.6 Hz, 2H), 2.58 (dd, *J* = 7.1, 2.6 Hz, 1H), 2.56 (s, 3H), 2.53 – 2.37 (m, 1H), 2.06 (qd, *J* = 11.3, 6.3 Hz, 2H), 1.94 (dt, *J* = 13.6, 6.8 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  197.6, 154.3 (dd, J = 291.7, 288.6 Hz), 138.8, 137.5, 133.1, 132.8 (t, J = 3.0 Hz), 129.0, 129.0, 128.6, 128.0 – 127.8 (m), 127.5 (d, J = 433.8 Hz), 127.5, 126.6, 90.1 (dd, J = 20.6, 15.2 Hz), 39.9, 36.6 (q, J = 28.0 Hz), 32.7, 31.4, 26.6.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.88 (t, J = 11.7 Hz, 3F), -89.23 (d, J = 40.7 Hz, 1F), -89.32 (d, J = 41.3 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>21</sub>H<sub>19</sub>F<sub>5</sub>ONa 405.1248; found 405.1255.

# 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-3,5-dimethoxybenzene (5h)



5h

**5h** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1,3-dimethoxy-5-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3i** (23.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5h** (35.2 mg, 88% yield) was isolated as a clear oil. TLC R*f* = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.26 (t, *J* = 7.4 Hz, 2H), 7.20 (t, *J* = 7.3 Hz, 1H), 7.02 (d, *J* = 7.1 Hz, 2H), 6.40 (t, *J* = 2.2 Hz, 1H), 6.33 (d, *J* = 1.1 Hz, 2H), 3.74 (s, 6H), 2.65 (qd, *J* = 13.9, 6.6 Hz, 2H), 2.55 – 2.46 (m, 1H), 2.45 – 2.35 (m, 1H), 2.10 – 1.96 (m, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 160.8, 154.2 (dd, J = 291.7, 286.8 Hz), 139.0, 134.4 – 134.3 (m), 129.1, 128.5, 127.1 (q, J = 277.3 Hz), 126.4, 106.3 (t, J = 3.0 Hz), 100.0, 90.7 (dd, J = 21.6, 13.7 Hz), 55.3, 39.8, 36.5 (q, J = 27.7 Hz), 32.7, 31.5, 29.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.68 (t, J = 11.7 Hz, 3F), -88.83 (d, J = 41.0 Hz, 1F), -90.12 (d, J = 40.5 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>21</sub>H<sub>21</sub>F<sub>5</sub>O<sub>2</sub>Na 423.1354; found 423.1350.

### 5-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzo[d][1,3]dioxole (5i)



5i

**5i** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 5- (3,3,3-trifluoroprop-1-en-2-yl)benzo[d][1,3]dioxole **3j** (21.6 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5i** (27.3mg, 71% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.33 – 7.25 (m, 2H), 7.22 (dd, J = 8.4, 6.3 Hz, 1H), 7.02 (d, J = 7.1 Hz, 2H), 6.77 (d, J = 8.0 Hz, 1H), 6.64 (s, 1H), 6.61 (d, J = 8.1 Hz, 1H), 5.98 (dd, J = 3.6, 1.5 Hz, 2H), 2.72 – 2.58 (m, 2H), 2.51 – 2.43 (m, 1H), 2.41 – 2.31 (m, 1H), 2.14 – 1.96 (m, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 154.1 (dd, J = 290.7, 286.7 Hz), 147.9, 147.0, 139.0, 129.1, 128.5, 127.1 (q, J = 277.1 Hz), 126.5, 126.1 – 126.0 (m), 121.8 (t, J = 2.9 Hz), 108.6 (t, J = 3.2 Hz), 108.4, 101.2, 90.3 (dd, J = 21.9, 13.9 Hz), 39.7, 36.5 (q, J = 27.7 Hz), 32.6, 31.7, 29.7. <sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.76 (t, J = 11.6 Hz, 3F), -90.39 (d, J = 43.6 Hz, 1F), -91.10 (d, J = 43.2 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>17</sub>F<sub>5</sub>O<sub>2</sub>Na 407.1041; found 407.1047.

## 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-fluoro-4-methoxybenzene (5j)

CF<sub>3</sub> Ρh MeC 5j

**5j** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 2-fluoro-1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3k** (22.0 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5j** (31.0 mg, 80% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.29 – 7.22 (m, 2H), 7.22 – 7.14 (m, 1H), 7.01 (dd, *J* = 8.2, 6.8 Hz, 1H), 6.97 (d, *J* = 7.1 Hz, 2H), 6.72 – 6.55 (m, 2H), 3.69 (s, 3H), 2.73 – 2.56 (m, 2H), 2.46 (dd, *J* = 14.5, 7.4 Hz, 1H), 2.41 – 2.29 (m, 1H), 2.20 – 2.04 (m, 1H), 2.04 – 1.91 (m, 1H), 1.82 (dt, *J* = 13.6, 6.8 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  163.5 (d, *J* = 247.1 Hz), 158.5 – 158.4 (m), 153.8 (t, *J* = 287.7 Hz), 139.2, 131.5 (d, *J* = 10.1 Hz), 129.0, 128.4, 127.1 (q, *J* = 277.2 Hz), 126.3, 117.1, 107.1 (d, *J* = 21.6 Hz), 99.3 (d, *J* = 26.1 Hz), 86.7 (dd, *J* = 23.7, 16.7 Hz), 55.5, 39.6, 36.4 (q, *J* = 27.4 Hz), 32.6, 31.5, 29.7.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.87 (t, J = 12.5 Hz, 3F), -88.03 (d, J = 41.2 Hz, 1F), -92.47 (d, J = 40.7 Hz, 1F), -105.72 – -115.29 (m, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>18</sub>F<sub>6</sub>ONa 411.1154; found 411.1161.

#### 3-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)thiophene (5k)



5k

**5k** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 3- (3,3,3-trifluoroprop-1-en-2-yl)thiophene **3l** (17.8 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5k** (27.7 mg, 80% yield) was isolated as a clear oil.

TLC Rf = 0.50 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.35 – 7.27 (m, 3H), 7.23 (t, *J* = 7.4 Hz, 1H), 7.07 (d, *J* = 7.2 Hz, 2H), 7.01 (ddd, *J* = 5.0, 2.1, 1.4 Hz, 1H), 6.94 (dd, *J* = 2.9, 1.1 Hz, 1H), 2.67 (qd, *J* = 13.8, 7.2 Hz, 2H), 2.50 (dd, *J* = 14.7, 7.3 Hz, 1H), 2.45 – 2.31 (m, 1H), 2.21 – 2.03 (m, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  153.5 (dd, *J* = 293.8, 286.1 Hz), 138.0, 131.5 (t, *J* = 4.3 Hz), 128.1, 127.6, 126.1 (q, *J* = 277.0 Hz), 125.7 (dd, *J* = 6.4, 2.0 Hz), 125.5, 124.8, 121.1 (t, *J* = 5.0 Hz), 85.7 (dd, *J* = 23.1, 13.1 Hz), 38.8, 35.7 (q, *J* = 27.5 Hz), 32.3, 30.2.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.63 (t, *J* = 12.2 Hz), -89.37 (d, *J* = 41.0 Hz), -90.12 (d, *J* = 41.2 Hz).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>15</sub>F<sub>5</sub>SNa 369.0707; found 369.0710.

## 5-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-methoxypyridine (5I)



51

**5I** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 2-methoxy-5-(3,3,3-trifluoroprop-1-en-2-yl)pyridine **3m** (20.3 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5I** (31.5 mg, 85% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.95 (s, 1H), 7.31 – 7.18 (m, 3H), 7.15 (t, *J* = 7.3 Hz, 1H), 6.95 (d, *J* = 7.2 Hz, 2H), 6.65 (d, *J* = 8.6 Hz, 1H), 3.88 (s, 3H), 2.58 (d, *J* = 7.1 Hz, 2H), 2.43 (dd, *J* = 14.7, 7.1 Hz, 1H), 2.32 (dd, *J* = 14.8, 7.1 Hz, 1H), 2.05 – 1.92 (m, 2H), 1.89 (dt, *J* = 13.6, 6.7 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  163.4, 154.1 (dd, *J* = 290.8, 287.9 Hz), 146.4 (t, *J* = 3.3 Hz), 138.7, 138.1 (t, *J* = 2.5 Hz), 129.1, 128.6, 127.0 (q, *J* = 277.5 Hz), 126.6, 121.3 (t, *J* = 2.6 Hz), 110.9, 87.6 (dd, *J* = 21.9, 15.2 Hz), 53.6, 39.8, 36.6 (q, *J* = 27.6 Hz), 32.6, 31.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.82 (t, *J* = 12.2 Hz, 3F), -89.83 (d, *J* = 42.7 Hz, 1F), -89.96 (d, *J* = 42.5 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>18</sub>F<sub>5</sub>NONa 394.1201; found 394.1208.

# 2-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)naphthalene (5m)



5m

**5m** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 1- (3,3,3-trifluoroprop-1-en-2-yl)naphthalene **3n** (22.2 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5m** (26.5 mg, 68% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.83 (dd, *J* = 6.0, 3.4 Hz, 1H), 7.81 (d, *J* = 8.6 Hz, 1H), 7.74 (dd, *J* = 6.0, 3.4 Hz, 1H), 7.55 (s, 1H), 7.50 (dd, *J* = 6.2, 3.2 Hz, 2H), 7.31 (dt, *J* = 8.5, 1.6 Hz, 1H), 7.28 – 7.17 (m, 3H), 7.00 (d, *J* = 6.5 Hz, 2H), 2.69 (d, *J* = 7.0 Hz, 2H), 2.62 (dd, *J* = 14.6, 7.3 Hz, 1H), 2.59 – 2.49 (m, 1H), 2.16 – 1.96 (m, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  154.4 (dd, *J* = 291.9, 287.5 Hz), 139.0, 133.2, 132.6, 130.2 – 129.6 (m), 129.1, 128.6, 128.3, 128.0, 127.6, 127.3 (t, *J* = 3.1 Hz), 127.1 (d, *J* = 277.3 Hz), 126.5, 126.4, 126.3, 125.8 (t, *J* = 2.7 Hz), 90.7 (dd, *J* = 20.8, 14.1 Hz), 39.9, 36.7 (q, *J* = 27.7 Hz), 32.8 31.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.74 (t, *J* = 12.4 Hz, 3F), -89.64 (d, *J* = 41.4 Hz, 1F), -89.79 (d, *J* = 42.7 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>19</sub>F<sub>5</sub>Na 413.1299; found 413.1304.

## 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-9,9-dimethyl-9H-fluorene (5n)



5n

**5n** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 9,9-dimethyl-1-(3,3,3-trifluoroprop-1-en-2-yl)-9H-fluorene **3o** (28.8 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5n** (28.3 mg, 62% yield) was isolated as a white solid.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.78 – 7.71 (m, 1H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.49 – 7.42 (m, 1H), 7.34 (pd, *J* = 7.4, 1.5 Hz, 2H), 7.26 – 7.22 (m, 3H), 7.19 (ddt, *J* = 11.0, 7.9, 1.4 Hz, 2H), 7.02 – 6.96 (m, 2H), 2.71 (dd, *J* = 13.8, 6.8 Hz, 1H), 2.62 (dd, *J* = 13.8, 7.3 Hz, 2H), 2.49 (dd, *J* = 14.7, 7.1 Hz, 1H), 2.04 (dddd, *J* = 22.1, 19.9, 10.7, 5.4 Hz, 3H), 1.47 (s, 3H), 1.45 (s, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  154.2 (dd, *J* = 290.7, 286.9 Hz), 154.0, 153.8, 139.1, 138.8, 138.6, 131.2 (t, *J* = 3.4 Hz), 129.0, 128.5, 128.2 (d, *J* = 55.8 Hz), 127.5, 127.2 (t, *J* = 2.9 Hz), 127.1, 126.4, 122.7, 122.3 (t, *J* = 2.9 Hz), 120.1, 91.0 (dd, *J* = 20.9, 14.0 Hz), 46.9, 39.8, 36.5 (q, *J* = 27.6 Hz), 32.7, 31.6, 29.7, 27.1, 26.9.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.81 (t, J = 11.8 Hz, 3F), -90.00 (d, J = 42.6 Hz, 1F), -90.71 (d, J = 44.1 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>28</sub>H<sub>25</sub>F<sub>5</sub>Na 479.1769; found 479.1761.

## (3-(difluoromethylene)-5-(2,2,2-trifluoroethyl)hex-1-yne-1,6-diyl)dibenzene (50)

Ph' 50

**50** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and (3-

(trifluoromethyl)but-3-en-1-yn-1-yl)benzene **3p** (19.6 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5o** (32.4 mg, 89% yield) was isolated as a clear oil.

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.43 (dd, *J* = 6.6, 3.0 Hz, 2H), 7.34 (dd, *J* = 4.5, 2.2 Hz, 3H), 7.31 (t, *J* = 7.5 Hz, 2H), 7.23 (t, *J* = 7.4 Hz, 1H), 7.19 (d, *J* = 7.1 Hz, 2H), 2.82 (dd, *J* = 13.9, 6.8 Hz, 1H), 2.72 (dd, *J* = 13.9, 7.5 Hz, 1H), 2.54 – 2.41 (m, 1H), 2.35 – 2.26 (m, 1H), 2.26 – 2.20 (m, 1H), 2.20 – 2.07 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  159.2 (dd, J = 297.3, 294.1 Hz), 138.8, 131.4, 129.2, 128.6, 128.4, 127.1 (q, J = 277.7 Hz), 126.5, 122.6, 94.4 (t, J = 5.6 Hz), 80.3 (dd, J = 8.0, 3.9 Hz), 39.5, 36.2 (q, J = 27.5 Hz), 33.4, 30.9.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.64 (t, J = 11.1 Hz, 3F), -78.07 (d, J = 14.3 Hz, 1F), -83.72 (d, J = 14.2 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>21</sub>H<sub>17</sub>F<sub>5</sub>Na 387.1143; found 387.1147.

#### N-(4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)-2-(4isobutylphenyl)propanamide (5p)



5p

**5p** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 2- (4-isobutylphenyl)-N-(4-(3,3,3-trifluoroprop-1-en-2-yl)phenyl)propanamide **3q** (37.5 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5p** (38.0 mg, 70% yield) was isolated as a white solid.

TLC Rf = 0.30 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.46 (dd, *J* = 16.4, 8.1 Hz, 1H), 7.34 – 7.26 (m, 2H), 7.24 (t, *J* = 8.1 Hz, 2H), 7.21 – 7.13 (m, 4H), 7.08 (d, *J* = 25.8 Hz, 1H), 6.99 (t, *J* = 6.8 Hz, 3H), 6.87 (d, *J* = 7.6 Hz, 1H), 3.69 (qd, *J* = 7.1, 3.3 Hz, 1H), 2.62 (d, *J* = 7.0 Hz, 2H), 2.48 (d, *J* = 7.2 Hz, 2H), 2.47 (dd, *J* = 12.5, 7.3 Hz, 2H), 2.40 (dd, *J* = 14.7, 6.9 Hz, 1H), 2.10 – 1.98 (m, 2H), 1.95 (dt, *J* = 12.0, 5.9 Hz, 1H), 1.91 – 1.82 (m, 1H), 1.60 (dd, *J* = 7.1, 3.8 Hz, 3H), 0.91 (dd, *J* = 6.6, 1.7 Hz, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  172.6, 154.1 (dd, *J* = 290.5, 288.6 Hz), 141.2, 139.0, 138.2, 138.0, 138.0, 133.3, 129.9, 129.2 (d, *J* = 2.2 Hz), 128.5, 127.4, 127.4, 127.0 (q, *J* = 277.4 Hz), 126.4, 123.9, 119.1, 119.0 (d, *J* = 4.8 Hz), 90.3 (dd, *J* = 21.8, 13.8 Hz), 47.8, 45.0, 39.7 (d, *J* = 3.9 Hz), 36.6 (qd, *J* = 27.5, 6.9 Hz), 32.8, 31.4, 30.2, 29.7, 22.4, 18.6 (d, *J* = 11.7 Hz).

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.69 (t, J = 14.1 Hz, 3F), -89.29 (d, J = 18.2 Hz, 1F), -89.96 (d, J = 40.9 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>32</sub>H<sub>34</sub>F<sub>5</sub>NONa 566.2453; found 566.2461.

# N-(4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)-5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide (5q)



**5q** was prepared according to the general procedure from allylbenzene **1a** (35.4 mg, 0.30 mmol, 3.0 equiv), sodium trifluoromethanesulfinate **2a** (46.8 mg, 0.30 mmol, 3.0 equiv) and 5- (2,5-dimethylphenoxy)-2,2-dimethyl-*N*-(4-(3,3,3-trifluoroprop-1-en-2-yl)phenyl)pentanamide **3r** (41.9 mg, 0.10 mmol, 1.0 equiv). The desired difluoroalkene **5q** (42.8 mg, 73% yield) was isolated as a white solid.

TLC Rf = 0.30 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.56 (d, *J* = 8.1 Hz, 1H), 7.39 – 7.24 (m, 5H), 7.21 (t, *J* = 7.3 Hz, 1H), 7.03 (d, *J* = 7.7 Hz, 2H), 7.00 (d, *J* = 7.4 Hz, 1H), 6.91 (d, *J* = 7.7 Hz, 1H), 6.67 (d, *J* = 7.4 Hz, 1H), 6.61 (s, 1H), 3.96 (s, 2H), 2.81 – 2.58 (m, 2H), 2.51 (dd, *J* = 14.6, 6.8 Hz, 1H), 2.43 (dd, *J* = 14.7, 6.8 Hz, 1H), 2.29 (s, 3H), 2.17 (s, 3H), 2.10 – 1.93 (m, 3H), 1.84 (d, *J* = 1.3 Hz, 4H), 1.35 (s, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  175.8, 156.9, 154.2 (dd, *J* = 291.8, 287.2 Hz), 139.0, 138.2, 136.6, 133.4, 130.4, 129.3, 129.2, 128.5, 127.1 (q, *J* = 277.4 Hz), 126.41 (s), 124.07 (s), 123.5, 120.9, 119.6, 119.5, 112.2, 90.4 (dd, *J* = 21.6, 13.7 Hz), 67.9, 42.9, 39.7, 37.7, 36.6 (q, *J* = 27.6 Hz), 32.8, 31.5, 29.7, 25.7, 25.6, 25.2, 21.4, 15.8.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.65 (t, J = 12.3 Hz, 3F), -89.29 (d, J = 40.8 Hz, 1F), -89.99 (d, J = 40.9 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>34</sub>H<sub>38</sub>F<sub>5</sub>NO<sub>2</sub>Na 610.2715; found 610.2728.

# 5. Large-scale experiment and further synthetic transformation: Large Scale (2.0 mmol) Experiment:



To an oven-dried 50 mL reaction vial equipped with a stir bar was added MesAcrMe<sup>+</sup> (16.0 mg, 0.04 mmol, 2 mol%), NaSO<sub>2</sub>CF<sub>3</sub> (936.0 mg, 6.0 mmol, 3.0 equiv), and K<sub>3</sub>PO<sub>4</sub> (848.2 mg, 4.0 mmol, 2.0 equiv). The vial was then charged with allylbenzene **1a** (709.1 mg, 6.0 mmol, 3.0 equiv) and 1-bromo-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3g** (500.0 mg, 2.0 mmol, 1.0 equiv) in anhyd MeCN (20 mL) *via* a syringe. The cap was sealed with Parafilm®, and the solution was irradiated with a 30 W blue LED light at room temperature for 24 hours. The temperature of the reaction was maintained at approximately 27 °C *via* a fan. The solution was transferred to a separatory funnel and diluted with deionized H<sub>2</sub>O (50 mL) and Et<sub>2</sub>O (50 mL). The layers were separated, and the aq layer was extracted with Et<sub>2</sub>O (4 X 40 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed *in vacuo* by rotary evaporation. Further purification was accomplished by SiO<sub>2</sub> column chromatography (gradient Hexane/EtOAc) to give the desired product **5f** (82% yield, 687 mg) as a white solid.

# Further synthetic transformation:



According to the literature,<sup>5</sup> to a 10 mL Schlenk flask was added difluoroalkene **5f** (41.8 mg, 0.10 mmol, 1.0 equiv), Pd(OAc)<sub>2</sub> (2.3 mg, 0.01 mmol, 10 mol%), potasium carbonate (27.6 mg, 0.20 mmol, 2.0 equiv) and 4-methoxyphenylboronic acid (30.4 mg, 0.20 mmol, 2.0 equiv). Then MeOH (0.5 mL) and H<sub>2</sub>O (0.5 mL) was added by syringe. The reaction mixture was stirred at 80 °C for 12 h. After cooling to room temperature, the solvent was removed under vacuum, and the residue was purified by columnchromatography on silica gel (petroleum ether/ethyl acetate 50:1) to afford the product as a white solid **5fa** (34.8 mg, 78% yield). TLC R*f* = 0.50 (Hexane/EtOAc = 5:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.57 (d, *J* = 8.7 Hz, 2H), 7.54 (d, *J* = 8.3 Hz, 2H), 7.28 (t, *J* = 7.4 Hz, 2H), 7.23 (t, *J* = 6.8 Hz, 3H), 7.04 (d, *J* = 7.2 Hz, 2H), 7.01 (d, *J* = 8.7 Hz, 2H), 3.87 (s, 3H), 2.71 (dd, *J* = 13.8, 6.6 Hz, 1H), 2.66 (dd, *J* = 13.8, 6.8 Hz, 1H), 2.58 (dd, *J* = 14.6, 6.3 Hz, 1H), 2.48 (dd, *J* = 14.6, 6.4 Hz, 1H), 2.22 – 1.81 (m, 3H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  159.3, 154.2 (dd, *J* = 291.5, 287.2 Hz), 139.9, 139.0, 132.9, 130.7, 129.2, 128.5, 128.5 (t, *J* = 3.1 Hz), 128.1, 126.8, 126.5, 114.3, 90.4 (dd, *J* = 21.2, 13.7 Hz), 55.4, 39.7, 36.6 (q, *J* = 27.5 Hz), 32.8, 31.3.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.65 (t, J = 11.9 Hz, 3F), -89.84 (d, J = 41.8 Hz, 1F), -90.10 (d, J = 41.9 Hz, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>26</sub>H<sub>23</sub>F<sub>5</sub>ONa 469.1561; found 469.1570.



According to the literature,<sup>9</sup> to a 10 mL Schlenk flask was added difluoroalkene **5f** (41.8 mg, 0.10 mmol, 1.0 equiv),  $Cs_2CO_3$  (3.3 mg, 0.01 mmol, 10 mol%), and TMSCN (30.0 mg, 0.30 mmol, 3.0 equiv), and then anhydrous MeCN (1.0 mL). The reaction mixture was stirred at rt for 24 h. Then the solvent was removed under vacuum, and the residue was purified by columnchromatography on silica gel (petroleum ether/ethyl acetate 30:1) to afford the product as a white solid **5fb** (30.2 mg, 71% yield).

TLC Rf = 0.40 (Hexane/EtOAc = 30:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.47 (d, *J* = 8.4 Hz, 2H), 7.20 (t, *J* = 7.1 Hz, 2H), 7.17 (d, *J* = 6.9 Hz, 1H), 6.99 (d, *J* = 8.4 Hz, 2H), 6.89 (d, *J* = 7.2 Hz, 2H), 2.69 (ddd, *J* = 14.4, 6.9, 3.5 Hz, 1H), 2.63 – 2.54 (m, 2H), 2.50 (dd, *J* = 13.9, 7.4 Hz, 1H), 2.05 – 1.98 (m, 1H), 1.94 – 1.90 (m, 1H), 1.89 – 1.79 (m, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  138.1, 137.7 (d, *J* = 16.0 Hz), 132.5, 131.3, 130.8 (d, *J* = 3.5 Hz), 129.6 (d, *J* = 2.8 Hz), 129.0, 128.7, 126.9, 126.7 (d, *J* = 277.5 Hz), 124.7, 112.0 (d, *J* = 47.2 Hz), 40.2, 37.0 (q, *J* = 28.0 Hz), 33.6, 32.8.

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.92 (t, *J* = 11.7 Hz, 3F), -121.33 (s, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>16</sub>F<sub>4</sub>NBrNa 448.0295; found 448.0304.



According to the literature,<sup>10</sup> to a 10 mL Schlenk flask was added difluoroalkene **5f** (41.8 mg, 0.10 mmol, 1.0 equiv), KO'Bu (44.8 mg, 0.20 mmol, 2.0 equiv), and then anhydrous THF (1.0 mL). The reaction mixture was stirred at rt for 24 h. Then the solvent was removed under vacuum, and the residue was purified by columnchromatography on silica gel (petroleum ether/ethyl acetate 30:1) to afford the product as a white solid **5fc** (30.0 mg, 63% yield, *E:Z* = 1.5:1).

TLC Rf = 0.40 (Hexane/EtOAc = 50:1, v/v).

For Z isomer:

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.37 (d, *J* = 8.5 Hz, 2H), 7.26 (t, *J* = 7.4 Hz, 2H), 7.21 (t, *J* = 7.3 Hz, 1H), 7.08 (d, *J* = 8.5 Hz, 2H), 7.01 (d, *J* = 7.1 Hz, 2H), 2.80 – 2.56 (m, 2H), 2.51 (ddd, *J* = 14.5, 7.8, 2.4 Hz, 1H), 2.41 (ddd, *J* = 14.5, 6.7, 2.7 Hz, 1H), 2.11 – 1.94 (m, 2H), 1.89 (dt, *J* = 13.7, 6.8 Hz, 1H), 1.22 (s, 9H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 155.5, 153.6, 139.4, 135.4 (d, J = 5.1 Hz), 131.1, 130.3 (d, J = 3.1 Hz), 129.2, 128.4, 126.3, 120.0, 98.3 (d, J = 36.0 Hz), 84.0 (d, J = 3.2 Hz), 39.8, 36.5 (q, J = 27.4 Hz), 33.1, 31.9, 28.6 (d, J = 1.7 Hz).

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>) δ -62.82 (t, *J* = 12.7 Hz, 3F), -75.14 (s, 1F).

For *E* isomer:

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.40 (d, *J* = 8.5 Hz, 2H), 7.29 – 7.23 (m, 2H), 7.20 (t, *J* = 7.3 Hz, 1H), 7.04 (d, *J* = 7.6 Hz, 2H), 7.00 (d, *J* = 7.3 Hz, 2H), 2.69 – 2.51 (m, 2H), 2.43 (dd, *J* = 14.3, 7.3 Hz, 1H), 2.35 (dd, *J* = 14.3, 6.8 Hz, 1H), 2.10 – 1.85 (m, 3H), 1.39 (s, 9H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  154.8, 152.9, 139.4 134.7, 131.3, 130.1(d, *J* = 4.1 Hz), 129.2 128.4, 126.3, 120.2, 97.3 (d, *J* = 27.0 Hz), 83.4(d, *J* = 2.9 Hz), 39.8, 36.5 (q, *J* = 27.3 Hz), 33.3, 33.0, 28.8 (d, *J* = 1.8 Hz).

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -62.73 (t, *J* = 11.8 Hz, 3F), -78.52 (s, 1F).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>25</sub>F<sub>4</sub>OBrNa 495.0917; found 495.0925.



According to the literature,<sup>11</sup> the 25 mL Schlenk tube was added difluoroalkene **5f** (41.8 mg, 0.10 mmol, 1.0 equiv) and toluene (1 mL) under argon. The Red-Al (80 ul, 3.5 M in toluene, 0.28 mol, 2.8 equiv) was added at 0 °C and the reaction was stirred for 2 h at 0 °C. Then the Red-Al (80 ul, 3.5 M in toluene, 0.28 mol, 2.8 equiv) was added and the mixture was stirred at 80 °C for another 24 h. The solution was cooled to room temperature and the crude product was purified by flash column chromatography on silica gel (PE) to afford the corresponding product **5fd** (32 mg, 80% yield).

# **6: Control Experiment:**

A) Radical trapping experiment:



To an oven-dried 4 mL reaction vial equipped with a stir bar was added MesAcrMe<sup>+</sup> (0.8 mg, 0.002 mmol, 2 mol%), NaSO<sub>2</sub>CF<sub>3</sub> (46.8 mg, 0.30 mmol, 3.0 equiv), K<sub>3</sub>PO<sub>4</sub> (42.4 mg, 0.20 mmol, 2.0 equiv), and TEMPO (46.8 mg, 0.30 mmol, 3.0 equiv). The vial was then charged with allylbenzene **1a** (35.5 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv) in anhyd MeCN (1 mL) *via* a syringe. The cap was sealed with Parafilm®, and the solution was irradiated with a 30 W blue LED light at room temperature for 24 hours. The temperature of the reaction was maintained at approximately 27 °C *via* a fan. The solution was stirred vigorously while being irradiated. After the reaction, the mixture was then filtered through a pad of Celite and concentrated under reduced pressure. The residue was then subjected to GC-MS and <sup>19</sup>F NMR analysis.

**B)** Radical clock experiment:



To an oven-dried 4 mL reaction vial equipped with a stir bar was added MesAcrMe<sup>+</sup> (0.8 mg, 0.002 mmol, 2 mol%), NaSO<sub>2</sub>CF<sub>3</sub> (46.8 mg, 0.30 mmol, 3.0 equiv), and K<sub>3</sub>PO<sub>4</sub> (42.4 mg, 0.20 mmol, 2.0 equiv). The vial was then charged with diethyl 2,2-diallylmalonate **6** (72.0 mg, 0.30 mmol, 3.0 equiv) and 1-methoxy-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **3a** (20.2 mg, 0.10 mmol, 1.0 equiv) in anhyd MeCN (1 mL) *via* a syringe. The cap was sealed with Parafilm®, and the solution was irradiated with a 30 W blue LED light at room temperature for 24 hours. The temperature of the reaction was maintained at approximately 27 °C *via* a fan. The solution was transferred to a separatory funnel and diluted with deionized H<sub>2</sub>O (20 mL) and Et<sub>2</sub>O (20 mL). The layers were separated, and the aq layer was extracted with Et<sub>2</sub>O (3 X 30 mL). The combined organic layers were washed with deionized H<sub>2</sub>O (2 X 20 mL) followed by brine (20 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed *in vacuo* by rotary evaporation. Further purification was accomplished by SiO<sub>2</sub> column

chromatography (gradient Hexane/EtOAc) to give the desired product **7** (86% yield, 42.3 mg, dr = 11:1) as a colorless oil.

TLC Rf = 0.35 (Hexane/EtOAc = 20:1, v/v).

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.21 (d, *J* = 8.7 Hz, 2H), 6.89 (d, *J* = 8.8 Hz, 2H), 4.49 – 4.02 (m, 4H), 3.81 (s, 3H), 2.44 (dt, *J* = 9.1, 6.6 Hz, 2H), 2.40 – 2.20 (m, 3H), 2.21 – 1.81 (m, 4H), 1.41 – 1.28 (m, 1H), 1.26 – 0.94 (m, 8H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  172.5, 172.4, 158.8, 156.4 – 150.5 (m), 129.3 (t, *J* = 3.2 Hz), 127.2 (d, *J* = 277.4 Hz), 125.3, 114.0, 91.4 (dd, *J* = 19.4, 16.1 Hz), 61.7, 58.5, 55.3, 41.4, 38.4, 37.9, 36.0, 33.2 (q, *J* = 27.5 Hz), 26.9, 26.0, 14.0 (d, *J* = 3.4 Hz).

<sup>19</sup>F NMR (565 MHz, CDCl<sub>3</sub>)  $\delta$  -64.32 (t, *J* = 11.8 Hz), -92.21 (d, *J* = 7.8 Hz).

HRMS (ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>24</sub>H<sub>29</sub>F<sub>5</sub>O<sub>5</sub>Na 515.1827; found 515.1839.

# 7. References:

- (1) Braun, M.-G.; Doyle, A. G. Palladium-Catalyzed Allylic C–H Fluorination. *J. Am. Chem. Soc.* **2013**, *135*, 12990–12993.
- (2) Lu, Z.-C.; Hennis, O.; Gentry, J.; Xu, B.; Hammond, G. B. Base-Promoted Radical Azofluoromethylation of Unactivated Alkenes. *Org. Lett.* **2020**, *22*, 4383–4388.
- (3) Xu, C.; Huang, W.-Q.; Zhang, R.-Z.; Gao, C.; Li, Y.-X.; Wang, M. Trifluoromethylations of Alkenes Using PhICF<sub>3</sub>Cl as Bifunctional Reagent. *J. Org. Chem.* **2019**, *84*, 14209–14216.
- (4) Cheng, B.; Liu, W.-B.; Lu, Z. Iron-Catalyzed Highly Enantioselective Hydrosilylation of Unactivated Terminal Alkenes. *J. Am. Chem. Soc.* **2018**, *140*, 5014–5017.
- (5) Shi, J.; Guo, L.-Y.; Hu, Q.-P.; Liu, Y.-T.; Li, Q.; Pan, F. Photoredox-Catalyzed Difunctionalization of Unactivated Olefins for Synthesizing Lactam-Substituted *gem*-Difluoroalkenes. *Org. Lett.* **2021**, *23*, 8822–8827.
- (6) Anand, D.; Sun, Z.-C.; Zhou, L. Visible-Light-Mediated β-C-H gem-Difluoroallylation of Aldehydes and Cyclic Ketones through C-F Bond Cleavage of 1-Trifluoromethyl Alkenes. Org. Lett. 2020, 22, 2371–2375.
- (7) Guo, Y.-Q.; Wang, R.; Song, H.; Liu, Y.; Wang, Q. Visible-Light-Induced Deoxygenation/Defluorination Protocol for Synthesis of γ,γ-Difluoroallylic Ketones. *Org. Lett.* **2020**, *22*, 709–713.
- (8) Lan, Y.; Yang, F.-Y.; Wang, C. Synthesis of *gem*-Difluoroalkenes via Nickel-Catalyzed Allylic Defluorinative Reductive Cross-Coupling. *ACS Catal.* **2018**, *8*, 9245–9251.
- (9) Jiang, L.-F.; Ren, B.-T.; Li, B.; Zhang, G.-Y.; Peng, Y.; Guan, Z.-Y.; Deng, Q.-H. Nucleophilic Substitution of *gem*-Difluoroalkenes with TMSNu Promoted by Catalytic Amounts of Cs<sub>2</sub>CO<sub>3</sub>. *J. Org. Chem.* **2019**, *84*, 6557–6564.
- (10) He, Y.-W.; Anand, D.; Sun, Z.-C.; Zhou, L. Visible-Light-Promoted Redox Neutral γ,γ Difluoroallylation of Cycloketone Oxime Ethers with Trifluoromethyl Alkenes via C–C and C–F Bond Cleavage. Org. Lett. **2019**, *21*, 3769–3773.
- (11) Poutrel, P.; Pannecoucke, X.; Jubault, P.; Poisson, T. Stereoselective Synthesis of Terminal Monofluoroalkenes from Trifluoromethylated Alkenes. *Org. Lett.* **2020**, *22*, 4858–4863.

# 8. NMR Spectra:

<sup>1</sup>H NMR spectrum of 1-(*tert*-butyl) 2-(hex-5-en-1-yl) (*R*)-pyrrolidine-1,2-dicarboxylate (1k) 600 MHz, CDCl<sub>3</sub>, 23 °C











90

80

70

. 60

50

40

. 30

20

. 10

110

190

180

. 170

160

. 150

140

. 130

. 120



S55



<sup>13</sup>C NMR spectrum of 3-methylbut-2-en-1-yl p-tolylcarbamate (1w)

. 151 MHz, CDCl₃, 23 ℃



#### <sup>1</sup>H NMR spectrum of hex-5-en-1-yl 3-(4,5-diphenyloxazol-2-yl)propanoate (1ab) 600 MHz, CDCl<sub>3</sub>, 23 °C

7.158 7.1587 7.1587 7.1587 7.1587 7.1587 7.1587 7.1587 7.1587 7.1587 7.1587 7.



<sup>13</sup>C NMR spectrum of hex-5-en-1-yl 3-(4,5-diphenyloxazol-2-yl)propanoate (1ab)



#### <sup>1</sup>H NMR spectrum of hex-5-en-1-yl 2-(4-isobutylphenyl)propanoate (1ac) 600 MHz, CDCI₃, 23 ℃



<sup>13</sup>C NMR spectrum of hex-5-en-1-yl 2-(4-isobutylphenyl)propanoate (1ac)



#### <sup>1</sup>H NMR spectrum of 3-(allyloxy)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17Hcyclopenta[*a*]phenanthren-17-one (1ad) 600 MHz, CDCl<sub>3</sub>, 23 °C



<sup>13</sup>C NMR spectrum of 3-(allyloxy)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17Hcyclopenta[*a*]phenanthren-17-one (1ad)



<sup>1</sup>H NMR spectrum of hex-5-en-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (1ag) 600 MHz, CDCI<sub>3</sub>, 23 °C



<sup>13</sup>C NMR spectrum of hex-5-en-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (1ag)



<sup>1</sup>H NMR spectrum of hex-5-en-1-yl-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (1ah) 600 MHz, CDCI<sub>3</sub>, 23 °C



<sup>13</sup>C NMR spectrum of hex-5-en-1-yl-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (1ah)



<sup>1</sup>H NMR spectrum of hex-5-en-1-yl 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate (1ai) 600 MHz, CDCl<sub>3</sub>, 23 °C



<sup>13</sup>C NMR spectrum of hex-5-en-1-yl 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate (1ai) 151 MHz, CDCl<sub>3</sub>, 23 °C





<sup>13</sup>C NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4a)



<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4a) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1yl)naphthalene (4b)



<sup>13</sup>C NMR spectrum of 1-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1yl)naphthalene (4b)



fl (ppm) <sup>19</sup>F NMR spectrum of 1-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1yl)naphthalene (4b)

565 MHz, CDCI<sub>3</sub>, 23 °C





<sup>13</sup>C NMR spectrum of 1-methoxy-4-(1,1,6,6,6-pentafluoro-4-phenethylhex-1-en-2-yl)benzene (4c)



<sup>19</sup>F NMR spectrum of 1-methoxy-4-(1,1,6,6,6-pentafluoro-4-phenethylhex-1-en-2-yl)benzene (4c) 565 MHz, CDCl<sub>3</sub>, 23 °C









<sup>19</sup>F NMR spectrum of 1-(1,1-difluoro-4-(2,2,2-trifluoroethyl)tetradec-1-en-2-yl)-4-methoxybenzene (4d) 565 MHz, CDCI<sub>3</sub>, 23 °C







<sup>13</sup>C NMR spectrum of 1-(4-(2-bromoethyl)-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4e)



<sup>19</sup>F NMR spectrum of 1-(4-(2-bromoethyl)-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4e) 565 MHz, CDCI<sub>3</sub>, 23 °C



# <sup>1</sup>H NMR spectrum of 1-(7-bromo-1,1-difluoro-4-(2,2,2-trifluoroethyl)hept-1-en-2-yl)-4-methoxybenzene (4f)

600 MHz, CDCl<sub>3</sub>, 23 ℃ ECCl3 28 C ECCl3


<sup>13</sup>C NMR spectrum of 1-(7-bromo-1,1-difluoro-4-(2,2,2-trifluoroethyl)hept-1-en-2-yl)-4methoxybenzene (4f)





<sup>1</sup>H NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl benzoate (4g)

<sup>13</sup>C NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl benzoate (4g)
151 MHz, CDCl<sub>3</sub>, 23 °C

CDCI <sub>3</sub> , 23 °C					
8.91 2.12 2.12 2.12 2.12		0.11 0.06 0.06 0.06	4.65	5.23	7.18 7.00 6.82 6.84 6.84 1.92 8.73 8.73 8.73 2.35 2.35 2.35
	00000000 <del>0</del>		- CO	66	



<sup>19</sup>F NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl benzoate (4g)







<sup>13</sup>C NMR spectrum of 1-(4-cyclohexyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4h)



<sup>19</sup>F NMR spectrum of 1-(4-cyclohexyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4h) 565 MHz, CDCl<sub>3</sub>, 23 °C



5 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -110 -120 -130 -140 f1 (ppm)

<sup>1</sup>H NMR spectrum of 3-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)hex-5-en-3-yl)-7-oxabicyclo[4.1.0]heptane (4i)







<sup>19</sup>F NMR spectrum of 3-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)hex-5-en-3-yl)-7oxabicyclo[4.1.0]heptane (4i) <sup>565</sup> MHz, CDCI₃, 23 °C



<sup>1</sup>H NMR spectrum of 13,13-difluoro-12-(4-methoxyphenyl)-10-(2,2,2-trifluoroethyl)tridec-12-enal (4j) 600 MHz, CDCI<sub>3</sub>, 23 °C





<sup>19</sup>F NMR spectrum of 13,13-difluoro-12-(4-methoxyphenyl)-10-(2,2,2-trifluoroethyl)tridec-12-enal (4j) 565 MHz, CDCI<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(*tert*-butyl) 2-(8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl) (2R)-pyrrolidine-1,2-dicarboxylate (4k)



<sup>13</sup>C NMR spectrum of 1-(*tert*-butyl) 2-(8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7en-1-yl) (2R)-pyrrolidine-1,2-dicarboxylate (4k)



<sup>19</sup>F NMR spectrum of 1-(*tert*-butyl) 2-(8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7en-1-yl) (2R)-pyrrolidine-1,2-dicarboxylate (4k)







<sup>19</sup>F NMR spectrum of 6,6-difluoro-5-(4-methoxyphenyl)-3-(2,2,2-trifluoroethyl)hex-5-enenitrile (4l) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of *tert*-butyl (5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)carbamate (4m)



<sup>13</sup>C NMR spectrum of *tert*-butyl (5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)carbamate (4m)



<sup>19</sup>F NMR spectrum of *tert*-butyl (5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1yl)carbamate (4m)



<sup>13</sup>C NMR spectrum of 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl acetate (4n)



565 MHz, CDCI<sub>3</sub>, 23 °C





fl (ppm)

<sup>1</sup>H NMR spectrum of 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl hexanoate (4o)



<sup>19</sup>F NMR spectrum of 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl hexanoate (40)



 $^{-1}$  H NMR spectrum of 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl 2-

phenoxyacetate (4p)



<sup>13</sup>C NMR spectrum of 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl 2-phenoxyacetate (4p)



fl (ppm) <sup>19</sup>F NMR spectrum of 5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl 2phenoxyacetate (4p)

565 MHz, CDCl₃, 23 ℃



<sup>1</sup>H NMR spectrum of 1-bromo-4-((5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1yl)oxy)benzene (4q)



<sup>13</sup>C NMR spectrum of 1-bromo-4-((5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)oxy)benzene (4q)



<sup>19</sup>F NMR spectrum of 1-bromo-4-((5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)oxy)benzene (4q)



3.06--

4.0 3.5 f1 (ppm)

2.05-₹ 2.00-≖

7.0

6.5

. 6. 0

5.5

. 5. 0

4.5

7.5

Η

3.0

\_bt 11232232

2.0

. 1. 5

. 1. 0

0.5

. 0. 0

. 2. 5



5 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -110 -120 -130 -140 f1 (ppm)

<sup>1</sup>H NMR spectrum of 1-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-2-(trifluoromethyl)cyclooctane (4s) 



<sup>13</sup>C NMR spectrum of 1-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-2-(trifluoromethyl)cyclooctane (4s)



<sup>19</sup>F NMR spectrum of 1-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-2-(trifluoromethyl)cyclooctane (4s) 565 MHz, CDCl<sub>3</sub>, 23 °C





## <sup>13</sup>C NMR spectrum of 2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-3-(trifluoromethyl)bicyclo[2.2.1]heptane (4t)



<sup>1</sup>H NMR spectrum of 1-(4-ethyl-1,1-difluoro-5-(trifluoromethyl)hept-1-en-2-yl)-4-methoxybenzene (4u) 



<sup>13</sup>C NMR spectrum of 1-(4-ethyl-1,1-difluoro-5-(trifluoromethyl)hept-1-en-2-yl)-4-methoxybenzene (4u)



<sup>19</sup>F NMR spectrum of 1-(4-ethyl-1,1-difluoro-5-(trifluoromethyl)hept-1-en-2-yl)-4-methoxybenzene (4u) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 6,6-difluoro-5-(4-methoxyphenyl)-3-methyl-3-(2,2,2-trifluoroethyl)hex-5-en-1-yl benzoate (4v)



<sup>13</sup>C NMR spectrum of 6,6-difluoro-5-(4-methoxyphenyl)-3-methyl-3-(2,2,2-trifluoroethyl)hex-5-en-1-yl benzoate (4v)



<sup>19</sup>F NMR spectrum of 6,6-difluoro-5-(4-methoxyphenyl)-3-methyl-3-(2,2,2-trifluoroethyl)hex-5-en-1-yl benzoate (4v) <sup>565</sup> MHz, CDCl<sub>3</sub>, 23 °C



0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -110 -120 -130 fl (ppm)

-140

<sup>1</sup>H NMR spectrum of 6,6-difluoro-5-(4-methoxyphenyl)-3,3-dimethyl-2-(trifluoromethyl)hex-5-en-1-yl *p*-tolylcarbamate (4w)



<sup>13</sup>C NMR spectrum of 6,6-difluoro-5-(4-methoxyphenyl)-3,3-dimethyl-2-(trifluoromethyl)hex-5-en-1-yl *p*-tolylcarbamate (4w)



<sup>19</sup>F NMR spectrum of 6,6-difluoro-5-(4-methoxyphenyl)-3,3-dimethyl-2-(trifluoromethyl)hex-5-en-1-yl *p*-tolylcarbamate (4w)

565 MHz, CDCI<sub>3</sub>, 23 °C



0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -105 -115 -125 -135 f1 (ppm)

<sup>1</sup>H NMR spectrum of 1-methoxy-4-(1,1,6,6,6-pentafluoro-4,4,5,5-tetramethylhex-1-en-2-yl)benzene (4x)



<sup>13</sup>C NMR spectrum of 1-methoxy-4-(1,1,6,6,6-pentafluoro-4,4,5,5-tetramethylhex-1-en-2-yl)benzene (4x)



<sup>19</sup>F NMR spectrum of 1-methoxy-4-(1,1,6,6,6-pentafluoro-4,4,5,5-tetramethylhex-1-en-2-yl)benzene (4x) 565 MHz, CDCI<sub>3</sub>, 23 °C 

-89.56 -89.64 -91.82 -91.90

F<sub>3</sub>C РМР

4x

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 fl (ppm) -105 -115 -125 -135 <sup>1</sup>H NMR spectrum of 1-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)hex-5-en-3-yl)pyrrolidin-2-one (4y)



<sup>13</sup>C NMR spectrum of 1-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)hex-5-en-3-yl)pyrrolidin-2-one (4y)



<sup>19</sup>F NMR spectrum of 1-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)hex-5-en-3-yl)pyrrolidin-2-one (4y) 565 MHz, CDCI<sub>3</sub>, 23 °C





<sup>13</sup>C NMR spectrum of 1-(4-butoxy-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-methoxybenzene (4z)











<sup>1</sup>H NMR spectrum of 2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-3-(trifluoromethyl)tetrahydro-2H-pyran (4aa) 

,PMP F<sub>2</sub>C ′CF<sub>3</sub> 4aa 1.06 1 2.13 *⊥* 1.23 *⊥* 2.01*-*∓ 1.02 ⊴ 3.19 ∡ 2.00≠ ਸ਼ਾਰ 1.03-127 - i i i

4.0 3.5 f1 (ppm) 7.5 7.0 6.5 6.0 5.5 5.0 4.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 <sup>13</sup>C NMR spectrum of 2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-3-(trifluoromethyl)tetrahydro-2H-

pyran (4aa)



<sup>19</sup>F NMR spectrum of 2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-3-(trifluoromethyl)tetrahydro-2Hpyran (4aa) 565 MHz, CDCI<sub>3</sub>, 23 °C



5 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -61 (ppm) -110 -120 <sup>1</sup>H NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 3-(4,5diphenyloxazol-2-yl)propanoate (4ab)

-130

-140



<sup>13</sup>C NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 3-(4,5-diphenyloxazol-2-yl)propanoate (4ab)



<sup>19</sup>F NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 3-(4,5diphenyloxazol-2-yl)propanoate (4ab) <sup>565</sup> MHz, CDCI<sub>3</sub>, 23 °C





<sup>1</sup>H NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4isobutylphenyl)propanoate (4ac)



<sup>13</sup>C NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4isobutylphenyl)propanoate (4ac)



<sup>19</sup>F NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4isobutylphenyl)propanoate (4ac)

565 MHz, CDCI<sub>3</sub>, 23 °C


<sup>13</sup>C NMR spectrum of (8R,9S,13S,14S)-3-((5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)oxy)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (4ad) 151 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 4-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)-1,2-dimethoxybenzene (4ae)



<sup>13</sup>C NMR spectrum of 4-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)-1,2dimethoxybenzene (4ae)



<sup>19</sup>F NMR spectrum of 4-(5,5-difluoro-4-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)pent-4-en-1-yl)-1,2dimethoxybenzene (4ae)



-5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 fl (ppm) 0 -105 -115 -125 -135

<sup>1</sup>H NMR spectrum of (4R,4aS,6R)-4,4a-dimethyl-6-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)-3methylhex-5-en-3-yl)-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one (4af) 

5







<sup>13</sup>C NMR spectrum of (4R,4aS,6R)-4,4a-dimethyl-6-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)-3-methylhex-5-en-3-yl)-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one (4af)



<sup>19</sup>F NMR spectrum of (4R,4aS,6R)-4,4a-dimethyl-6-(1,1,1,6,6-pentafluoro-5-(4-methoxyphenyl)-3methylhex-5-en-3-yl)-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one (4af) <sup>565</sup> MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (4ag)



<sup>13</sup>C NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(1-(4chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (4ag)



<sup>19</sup>F NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (4ag)



5 0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -110 -120 -130 -140 f1 (ppm)

<sup>1</sup>H NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl (1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (4ah)





<sup>13</sup>C NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl (1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (4ah)



<sup>19</sup>F NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl (1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (4ah) 565 MHz, CDCI<sub>3</sub>, 23 °C



S113

<sup>1</sup>H NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate (4ai)



<sup>13</sup>C NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate (4ai)



<sup>19</sup>F NMR spectrum of 8,8-difluoro-7-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)oct-7-en-1-yl 2-(4-(2,2dichlorocyclopropyl)phenoxy)-2-methylpropanoate (4ai) <sup>565</sup> MHz, CDCI<sub>3</sub>, 23 ℃



S115

4.0 f1 (ppm) 3.5

. 3. 0 2.5

2.0

1.5

1.0

0.5

0.0

4.5

8.0

7.5

7.0

6.5

. 6. 0 . 5. 5 5.0



<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(tert-butyl)benzene (5a) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(trifluoromethoxy)benzene (5b) 



<sup>13</sup>C NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(trifluoromethoxy)benzene (5b) 151 MHz, CDCI<sub>3</sub>, 23 °C



<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(trifluoromethoxy)benzene (5b) 565 MHz, CDCI<sub>3</sub>, 23 °C







<sup>19</sup>F NMR spectrum of methyl 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzoate (5c) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(methylsulfonyl)benzene (5d) 2.569 2.564 2.5666 2.566 2.566 2.566 2.566 2.566 2.566 2.566 2.566 2.566 2.566 2.566 CF<sub>3</sub> F Ph MeO<sub>2</sub>S 5d 1.18 -3.46-5.04F 2.07-I 2.234 1.14 -1 2.00-2 3.21 . 7.5 2.0 8.0 7.0 6.5 6.0 5.5 5.0 4.5 4.0 f1 (ppm) 3.5 3.0 2.5 1.5 1.0 0.5 0.0

<sup>13</sup>C NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(methylsulfonyl)benzene (5d)



<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-(methylsulfonyl)benzene (5d) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzonitrile (5e)





<sup>19</sup>F NMR spectrum of 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzonitrile (5e) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-bromobenzene (5f) 



<sup>13</sup>C NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-bromobenzene (5f)



<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4-bromobenzene (5f) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(3-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)ethan-1-one (5g)

600 MHz, CDCl₃, 23 ℃

888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888
888</td





<sup>19</sup>F NMR spectrum of 1-(3-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)ethan-1-one (5g) 565 MHz, CDCl<sub>3</sub>, 23 °C



-70 -80 f1 (ppm) -10 -30 -90 -100 -110 -120 -130 -20 -40 -50 -60 -140 -150



<sup>13</sup>C NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-3,5-dimethoxybenzene (5h)



<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-3,5-dimethoxybenzene (5h) <sup>565</sup> MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 5-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzo[d][1,3]dioxole (5i)





<sup>19</sup>F NMR spectrum of 5-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)benzo[d][1,3]dioxole (5i) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-fluoro-4-methoxybenzene (5j) 600 MHz, CDCl<sub>3</sub>, 23 ℃ 860 MHz, CDCl<sub>3</sub>, 23 ℃ 861 Hz, CDCl<sub>3</sub>, 23 ℃ 862 Hz, CDCL<sub>3</sub>, 23 ℃



<sup>13</sup>C NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-fluoro-4-methoxybenzene (5j)



<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-fluoro-4-methoxybenzene (5j) 565 MHz, CDCl<sub>3</sub>, 23 °C







<sup>19</sup>F NMR spectrum of 3-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)thiophene (5k) 565 MHz, CDCl<sub>3</sub>, 23 °C



0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -110 -120 -130 -140 f1 (ppm)

<sup>1</sup>H NMR spectrum of 5-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-methoxypyridine (5l)



<sup>13</sup>C NMR spectrum of 5-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-methoxypyridine (5l)



<sup>19</sup>F NMR spectrum of 5-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-2-methoxypyridine (5I) 565 MHz, CDCI<sub>3</sub>, 23 °C







<sup>19</sup>F NMR spectrum of 2-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)naphthalene (5m) 565 MHz, CDCI<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-9,9-dimethyl-9H-fluorene (5n) 600 MHz, CDCl₃, 23 ℃ 800 MHz, CDCl₃, 20 ℃ 800 MHz, 20 € 800 MHz, 20



<sup>13</sup>C NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-9,9-dimethyl-9H-fluorene (5n)



S135

<sup>19</sup>F NMR spectrum of 1-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-9,9-dimethyl-9H-fluorene (5n) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of (3-(difluoromethylene)-5-(2,2,2-trifluoroethyl)hex-1-yne-1,6-diyl)dibenzene (50)





<sup>19</sup>F NMR spectrum of (3-(difluoromethylene)-5-(2,2,2-trifluoroethyl)hex-1-yne-1,6-diyl)dibenzene (50) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of *N*-(4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)-2-(4-isobutylphenyl)propanamide (5p)

600 MHz, CDCl₃, 23 °C 800 MHz, CDCl₃, 23 °C 810 Hz, CDCl₃, 20 °C 810 Hz, CDCl₂, 20 °C 810 Hz, CDCl₂, 20 °



<sup>13</sup>C NMR spectrum of *N*-(4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)-2-(4-isobutylphenyl)propanamide (5p)



<sup>19</sup>F NMR spectrum of *N*-(4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)-2-(4-isobutylphenyl)propanamide (5p)



<sup>13</sup>C NMR spectrum of *N*-(4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)phenyl)-5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide (5q)









<sup>1</sup>H NMR spectrum of 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4'-methoxy-1,1'-biphenyl (5fa)

<sup>13</sup>C NMR spectrum of 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4'-methoxy-1,1'-biphenyl (5fa) <sup>151</sup> MHz, CDCl<sub>3</sub>, 23 °C



<sup>19</sup>F NMR spectrum of 4-(4-benzyl-1,1,6,6,6-pentafluorohex-1-en-2-yl)-4'-methoxy-1,1'-biphenyl (5fa) 565 MHz, CDCI<sub>3</sub>, 23 °C


<sup>13</sup>C NMR spectrum of (*E*)-5-benzyl-3-(4-bromophenyl)-2,7,7,7-tetrafluorohept-2-enenitrile (5fb)



0 -10 -20 -50 -70 -140 -30 -40 -60 -80 f1 (ppm) -90 -100 -110 -120 -130 -150 -160 <sup>1</sup>H NMR spectrum of (*Z*)-1-(4-benzyl-1-(tert-butoxy)-1,6,6,6-tetrafluorohex-1-en-2-yl)-4-bromobenzene (5fc)

600 MHz, CDCl<sub>3</sub>, 23 ℃ 600 MLz, CDCl<sub>3</sub>, 20 CL 600



<sup>19</sup>F NMR spectrum of (*Z*)-1-(4-benzyl-1-(tert-butoxy)-1,6,6,6-tetrafluorohex-1-en-2-yl)-4-bromobenzene (5fc)



0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -12 fl (ppm)

<sup>1</sup>H NMR spectrum of (*E*)-1-(4-benzyl-1-(tert-butoxy)-1,6,6,6-tetrafluorohex-1-en-2-yl)-4-bromobenzene (5fc)



<sup>13</sup>C NMR spectrum of (*E*)-1-(4-benzyl-1-(tert-butoxy)-1,6,6,6-tetrafluorohex-1-en-2-yl)-4bromobenzene (5fc)



90 80 fl (ppm) <sup>19</sup>F NMR spectrum of (*E*)-1-(4-benzyl-1-(tert-butoxy)-1,6,6,6-tetrafluorohex-1-en-2-yl)-4-bromobenzene (5fc) 565 MHz, CDCI<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of (*Z*)-1-(4-benzyl-1,6,6,6-tetrafluorohex-1-en-2-yl)-4-bromobenzene (5fd) 600 MHz, CDCl<sub>3</sub>, 23 ℃ #100 MHz, CDCl<sub>3</sub>, 23 ℃





<sup>13</sup>C NMR spectrum of (Z)-1-(4-benzyl-1,6,6,6-tetrafluorohex-1-en-2-yl)-4-bromobenzene (5fd)



<sup>19</sup>F NMR spectrum of (*Z*)-1-(4-benzyl-1,6,6,6-tetrafluorohex-1-en-2-yl)-4-bromobenzene (5fd) 565 MHz, CDCl<sub>3</sub>, 23 °C



<sup>1</sup>H NMR spectrum of diethyl 3-(4,4-difluoro-3-(4-methoxyphenyl)but-3-en-1-yl)-4-(2,2,2trifluoroethyl)cyclopentane-1,1-dicarboxylate (7)



<sup>13</sup>C NMR spectrum of diethyl 3-(4,4-difluoro-3-(4-methoxyphenyl)but-3-en-1-yl)-4-(2,2,2-trifluoroethyl)cyclopentane-1,1-dicarboxylate (7)

